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Vaccinia replication is complex, as it involves both producing new infectious particles as well as a myriad of
proteins dedicated to combating the host’s immune response. Although these proteins are often called “non-
essential”, they are frequently needed for the virus to achieve maximum virulence in vivo. Two of these
proteins are the vaccinia complement control protein (VCP) and A56, the vaccinia hemagglutinin. VCP had
been previously described as a virulence factor that was secreted from infected cells and blocked the activation
of the complement cascade; A56 was known to bind another viral protein, K2. We have found that VCP and
A56 interact on the surface of infected cells, and that this interaction is important for full vaccinia virulence in
vivo. The first part of this thesis focuses on showing a direct interaction between A56 and VCP on the surface
of infected cells, and that the N-terminal cysteine of VCP is needed for this interaction. The next section
establishes that this interaction occurs via an intermolecular disulfide bridge between the two proteins in a
transfection model, and also extends this phenomenon to VCP homologs from other poxviruses. Mutagenesis
shows that VCP binds to the 3rd cysteine (residue 162) of the ectodomain of A56. We also begin to show that
viruses that cannot form the A56/VCP complex are attenuated in vivo, using a virus V where the N-terminal
cysteine of VCP is mutated. In the last section, we create a virus with a recombinant A56 protein that cannot
bind VCP. We show that this virus is attenuated in intranasal and intradermal models of infection in mice;
infections done in C3-knockout mice suggest that this attenuation is complement dependent. This work
shows that VCP is not only important as a secreted protein, and that the A56/VCP complex is important for
the virus to achieve maximum pathogenesis in vivo. These results also provide insight into the contributions
of the A56 protein to vaccinia virulence in an infection, and for the first time tests a site-directed A56 mutant
in vivo.
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Abstract 
 
THE VACCINIA A56/VCP COMPLEX: MECHANISM AND IMPLICATIONS 
FOR PATHOGENESIS 
BRIAN C. DEHAVEN 
STUART N. ISAACS  
Vaccinia replication is complex, as it involves both producing new infectious particles as 
well as a myriad of proteins dedicated to combating the host’s immune response.  
Although these proteins are often called “non-essential”, they are frequently needed for 
the virus to achieve maximum virulence in vivo.  Two of these proteins are the vaccinia 
complement control protein (VCP) and A56, the vaccinia hemagglutinin.  VCP had been 
previously described as a virulence factor that was secreted from infected cells and 
blocked the activation of the complement cascade; A56 was known to bind another viral 
protein, K2.  We have found that VCP and A56 interact on the surface of infected cells, 
and that this interaction is important for full vaccinia virulence in vivo.  The first part of 
this thesis focuses on showing a direct interaction between A56 and VCP on the surface 
of infected cells, and that the N-terminal cysteine of VCP is needed for this interaction.  
The next section establishes that this interaction occurs via an intermolecular disulfide 
bridge between the two proteins in a transfection model, and also extends this 
phenomenon to VCP homologs from other poxviruses.  Mutagenesis shows that VCP 
binds to the 3rd cysteine (residue 162) of the ectodomain of A56.  We also begin to show 
that viruses that cannot form the A56/VCP complex are attenuated in vivo, using a virus 
where the N-terminal cysteine of VCP is mutated.  In the last section, we create a virus 
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with a recombinant A56 protein that cannot bind VCP. We show that this virus is 
attenuated in intranasal and intradermal models of infection in mice; infections done in 
C3-knockout mice suggest that this attenuation is complement dependent.  This work 
shows that VCP is not only important as a secreted protein, and that the A56/VCP 
complex is important for the virus to achieve maximum pathogenesis in vivo.  These 
results also provide insight into the contributions of the A56 protein to vaccinia virulence 
in an infection, and for the first time tests a site-directed A56 mutant in vivo. 
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CHAPTER ONE: The vaccinia virus, the host complement system, and 
poxvirus regulators of complement activation 
 
Introduction 
  
 The Poxviridae family includes some of the most important pathogens in human 
history.  The variola virus is the causative agent of smallpox and was responsible for 
hundreds of millions of deaths worldwide (30).  Fortunately, after a successful 
vacciniation campaign with the closely related vaccinia virus (VACV), smallpox was 
declared eradicated in 1980.  Today, VACV is still widely studied for a variety of 
reasons.  It serves as model for other, more virulent poxviruses, such as variola and 
monkeypox viruses.  It can also be used to study the immune response to an infection and 
can be used as a recombinant vaccine against other infectious diseases.  It even shows 
some promise as an oncolytic cancer vector (70).  Vaccinia, variola, cowpox, monkeypox 
viruses and the mousepox-causing ectromelia virus are all orthopoxviruses and are highly 
related.  Their genomes are highly conserved, and proteins in one virus often have the 
same activity in others (65).  
 VACV devotes a large part of its genome to non-essential virulence genes, which 
combat the hosts’ immune response (65).  One of these is VCP, the vaccinia complement 
control protein (59).  It is able to interfere with the host complement cascade at multiple 
steps, and is important for full virulence in vivo (23, 37, 50).  VCP was initially 
characterized as a secreted protein.  Here, we will show that it also is expressed on the 
surface of infected cells, through an interaction with another viral protein, A56.  We will 
also show that this interaction occurs with other orthopoxvirus species’ proteins, and that 
this interaction is needed for maximum virulence in vivo.   
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The vaccinia virus 
VACV is the most studied poxvirus and serves as its model orthopoxvirus.  
Structurally, it is a large DNA enveloped virus, with two infectious forms.  Internally, the 
virus is composed of a dumbbell-shaped core with two lateral bodies on either side.  
These structures are enveloped by one or more lipid bilayers, as there are two forms of 
infectious VACV.  The first and most abundant is mature virs (MV), which has a single 
lipid bilayer studded with non-glycosylated viral proteins (82).  The other infectious form 
is enveloped virus (EV).   These virions are MV particles with an additional viral 
membrane, one that contains a different set of glycosylated viral proteins as well as host 
proteins (115).  Notably, the entry/fusion machinery of VACV is only on the MV 
membrane (83), so the outer envelope on EV must dissolve before entry of EV can occur 
(63).  This has led to the hypothesis that the EV membrane’s functional purpose is 
immune evasion.  That is, it “hides” neutralizing antibody targets from the host.  EV 
particles are important for spread within the host, as mutations that interfere with EV 
formation and release significantly attenuate the virus (75, 92, 122, 138).  
The genome of VACV is linear and covalently closed at both ends.  There are 
inverted terminal repeats at either end which flank the large number of open reading 
frames (ORF) found in VACV (7).  Historically, genes in VACV are often named for 
where they lie on a HindII restriction digest map (28). For VACV (Copenhagen strain) 
this digest results in 15 fragments (named A-O in order of decreasing size); each ORF on 
a fragment is named with sequential numbers and its orientation (38).  Thus, A56R is the 
56th ORF in the HindIII A fragment, and it reads to the right (R).  There is also gross 
organization of the VACV genome.  The genes in the center of the genome tend to be 
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necessary for replication and well conserved; conversely, those on either arm often 
encode virulence factors.  These genes are not necessary for replication in tissue culture 
and vary more widely among viral isolates and species (73).  
  
Vaccinia virus lifecycle 
VACV entry into a cell is complex and can occur via multiple routes.  An entry 
receptor for VACV has not been identified, and the virus can enter almost any type of 
cell.  VACV has highly complex entry/fusion machinery, rather than a single protein, like 
most other viruses.  The entry fusion complex is a large complex of 9 proteins (83).  
Mature virus (MV) particles have been observed entering cells via membrane fusion, 
endocytosis, and macropinocytosis (17, 79, 121, 137).  In addition, EV particles must 
shed their outer membrane to expose the entry/fusion complex (63).   
Once inside the cell, the virus uncoats and gene expression begins, although some 
early transcription starts before uncoating.  Unlike nearly all other DNA viruses, VACV 
replicates in the cytoplasm of infected cells, in a distinct cellular environment called the 
viral factory (54).  This means that the virus must encode and package its own enzymatic 
replication machinery.  VACV gene expression can be separated temporally into three 
classes: early, intermediate, and late genes.   Early gene expression occurs before viral 
DNA replication, and includes proteins necessary for DNA replication, as well as 
proteins that combat the host’s immune response (104). By a mechanism that is still not 
completely understood, VACV DNA initiates replication by self-priming in the inverted 
terminal repeats (82); this results in long DNA concatamers which are cleaved by a viral 
resolvase enzyme into single-genome units (22, 34).   
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DNA replication is followed by intermediate and late gene expression.  There are 
only a small number of intermediate genes, and several of these are transcription factors 
for late gene expression.   The late genes include structural proteins needed for viral 
morphogenesis and transcription machinery to be packaged into viruses.  During 
morphogenesis, MV particles are formed; although they make up the majority of the virus 
produced, they only leave the cell upon lysis or necrosis.  A small proportion of these 
particles travel on microtubles away from the viral factory, where they gain two 
additional lipid membranes from endosomal or Golgi apparatus (102, 120).  This form of 
virus, called intracellular enveloped virus (IEV), is then transported to the cell surface on 
microtubules (43).  Once there, the outermost membrane fuses with the cellular 
membrane to expose an EV particle.  Initially, the EV particle remains attached to the 
surface of the cell and is call the cell associated EV (CEV) (4, 5).  While some CEV is 
released from the cell, in other cases the virus drives actin polymerization underneath the 
particle, causing the CEV to be protruded out from the cell in an actin tail; these tails can 
project the virus into neighboring cells (33, 88). 
 
Vaccinia virus infection and the complement system 
 
In the course of an infection, the VACV encounters and must contend with the 
host’s immune system.   It is well established that after initial challenge in both humans 
and animal models robust B- and T-cell responses develop (141) and are protective 
against subsequent infection (41, 53).  This can extend to different poxviruses; the most 
famous case is of course scarification with VACV protecting against smallpox (30).  
However, other arms of the immune system are also important for protection, and one of 
these is the complement system.   
  5 
 
The complement cascade 
 “Complement” is a highly complex and organized system of more than 30 
proteins that makes up one of the earliest acting components of the immune system.  
Within minutes of an infection, it starts to label an invading pathogen as “non-self” and 
begins a chain reaction that can lead to the release of chemotaxic molecules and to the 
formation of lytic pores.  The complement cascade made up of mostly sequentially acting 
proteins named C1 to C9 as well as other accessory proteins.  The cascade is centered 
around the multifunctional C3 protein (134, 135). 
 There are three different activation pathways for complement: classical, 
alternative, and mannose-binding lectin.   While they have different activators and initial 
steps, all three merge with the formation of C3 convertases and can terminate in the 
formation of the membrane attack complex (MAC), a multi-protein pore-forming 
structure that destroys membrane integrity and can cause cell lysis of pathogens and 
infected cells.  The classical pathway was the first to be discovered.  In this pathway, 
complement component C1 recognizes antibody bound to a foreign object or pathogen.  
Lectin binds carbohydrate residues found on pathogens.  The alternative pathway, by 
contrast, does not have a specific activator.  It starts with spontaneous cleavage of C3 to 
its active form of C3b.  All three pathways converge on formation of a C3 convertase, a 
catalytic complex that creates more activated C3.  When classical and mannose-binding 
lectin pathways are activated, C2 and C4 molecules are cleaved into their active 
fragments, C4b and C2a.  They combine to form the classical C3 convertase, C4bC2a.  
The alternative pathway convertase consists of C3 bound to activated factor B, C3bBb.  
As more and more C3b is created by these complexes, some C3b binds to the C3 
  6 
convertases, changing them to C5 convertases, referred to as C3bBbC3b or C4bC2aC3b.  
These new enzymatic complexes cleave C5 into C5a and the larger C5b, which then 
recruits C6 through C9, which form the membrane attack complex.  C6 binds C5b and 
recruits C7; C7 and C8 have hydrophobic sites that allow membrane insertion.  C8 also 
recruits 10-16 subunits of C9, which forms the actual lytic pore. 
There are several receptors for complement components on immune system cells.  
Several of these respond to C3b, such as complement receptor 1 (CR1), CR2, CR3 and 
CR4.  There are also receptors for the cleaved fragments of C3a and C5a, known as C3a 
receptor (C3aR) and C5aR.  These receptors can mediate phagocytosis of opsonized 
particles, chemotaxis of inflammatory cells to the site of an infection and initiation of the 
adaptive arm of the immune system (26).   
 
Host regulators of complement 
 Complement has the ability to damage not only pathogens but also the host’s own 
cells.  To prevent this from occurring, a protein family called regulators of complement 
activity (RCA) inhibits the complement cascade.  These include both membrane-bound 
and soluble inhibitors of complement.  There are two main ways to deactivate the 
complement cascade.  The first is the Factor I mediated degradation of activated C3 and 
C4 molecules to inactive forms.  Factor I activity requires co-factor proteins.  Proteins 
with cofactor activity include CR1, factor H, C4-binding protein, factor H like protein 1 
(FHL-1) and membrane cofactor protein (MCP).  Other proteins have decay accelerating 
activity (DAA), which is the ability to dissociate C3 convertase complexes. Proteins with 
DAA include CR1, factor H, FHL-1 and decay-accelerating factor (DAF) (134, 135).   
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Importantly, these proteins all share the same structural building block, known as 
a short consensus repeat (SCR).  These are small domains (60 to 70 amino acids) that 
contain two disulfide bridges.  The SCR domains are found in repeats (from 4 to 30).   
Several pathogens encode their own complement regulatory proteins, some of which are 
made up of SCR domains.  Although it does not contain SCR domains, the host protein 
CD59 is also an RCA, and prevents formation of the membrane attack complex.   
 
Viruses and complement 
Historically, viruses were not thought of as a main target of complement.  
However, many studies have now shown that complement acts against viral pathogens, 
and that viruses have responded by evolving defenses against the complement system 
(61).  Complement is able to lyse both viral particles and infected cells; this has been 
shown in many viruses, such as HIV, orthopoxviruses, herpesvirus, and influenza virus 
(10).  Complement molecules are also able to opsonize viral particles through C3, C4 and 
C5 deposition, which can lead to neutralization and/or phagocytosis by immune cells.   
A deficient complement response, often shown experimentally with knockout 
mice, can also affect the activity of the adaptive immune system.  C3 knockout (C3-/-) 
mice challenged with influenza virus exhibit impaired T-cell responses (56).  Similar 
results were seen in complement-deficient mice infected with West Nile Virus and 
LCMV and vaccinia (37, 77, 118). 
More recently, studies have shown that complement is important for survival from 
poxvirus infections.  For instance, a fully functional complement system is needed for 
normally resistant mice to survive infection with ectromelia virus.  C3-/- mice suffered 
higher mortality rates than wild type mice in footpad, ear pinnea, and intranasal models 
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of infection (84).  These higher rates were also seen with both C4-/- and fB -/- mice.  In 
addition, complement is likely important during a secondary poxvirus infection.  A recent 
study by Benhnia, et al characterized a monoclonal anti-VACV Ab that fixed 
complement (8).  This Ab provided greater in vitro virus neutralization and in vivo 
protection against challenge than other, similar antibodies that were not complement-
fixing.   
 
Viral inhibition of complement 
To respond to host complement, viruses have devised ways to interfere with the 
complement system during an infection.  Many microorganisms such as bacteria and 
fungi actually incorporate host RCAs and several viruses have also evolved to do this 
(61).  These include poxviruses, paramyxoviruses and several retroviruses.  VACV has 
been shown to incorporate DAF, MCP and CD59 into EV particles, making that form of 
the virus relatively resistant to complement neutralization (129).  Similarly, HTLV-1 
incorporates DAF and CD59, HIV incorporates DAF, CD59, and factor H, and SIV 
incorporates DAF, CD59, and MCP into their envelopes during viral budding (72, 81, 
103, 117).   The paramyxoviruses simian virus 5, and the mumps virus incorporate MCP 
into virion particles, as well (52). 
In addition to these host proteins, some viruses encode their own regulators of 
complement.  These can either be evolutionarily related to host complment control 
proteins, or without obvious homology.   Many poxviruses encode an RCA homolog 
(10).  Such a protein was first characterized in VACV and named the vaccinia 
complement control protein (VCP).  It has been studied extensively and will be reviewed 
in greater detail below.  Two other viral families also encode complement inhibitors, 
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herpesviruses and flaviviruses.  Both HSV-1 and HSV-2 encode a transmembrane 
protein, gC, that binds C3b and protects virions from complement-mediated 
neutralization (32, 42, 44).  Interestingly, gC has no homology to host RCA proteins.  
Herpesvirus Samiri and HHV-8, on the other hand, encode transmembrane complement 
control proteins that contain SCR domains (1, 2, 99).   The flavivirus protein NS1 binds 
to the surface on infected cells and has also recently been shown to be a complement 
inhibitory protein (6, 20).  Like gC, it has no homology to host RCA proteins. 
 
 
The vaccinia complement control protein  
VCP is a 263 amino acid protein (243 residues after cleavage of its signal 
sequence) located in the C3L ORF of VACV (59).  It is the most abundant viral protein 
secreted from vaccinia-infected cells.  Structurally, VCP is made up of four SCR domains 
(59).  VCP has high levels of homology to host RCA proteins, including C4-binding 
protein, MCP and DAF (57).  Electrostatic modeling predicts that the first SCR has a net 
positive charge, while SCRs two and three have a negative charge (107).  VCP also 
contains an unpaired N-terminal cysteine just prior to the start of the first SCR domain.  
This cysteine can mediate homodimerization of the protein, which occurs with a minority 
of VCP molecules (68).  When purified, these homodimers have a higher level of 
complement regulatory activity than monomers.   
 VCP is able to block the complement cascade at multiple steps of both the 
classical and alternative pathways.  VCP can act as a cofactor in the in factor I mediated 
cleavage of both C3b and C4b (76, 100).  VCP also possesses decay accelerating activity, 
the ability to disassociate both C3 and C5 convertases (76).  The varying activities of 
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VCP can be attributed to specific SCR domains in the protein.  C3 and C4 binding along 
with cofactor activity occur in the first three SCR domains.  Classical pathway decay-
accelerating activity occurs in SCR domains 1 and 2; alternative pathway DAA happens 
in domains 2 to 4 (86).  VCP also has two heparin binding sites, one each in SCRs 1 and 
4 (86, 116).  These have been shown to mediate cell-surface binding of recombinant 
protein (68, 116). 
Initially, VCP was shown to have complement regulatory activity by its ability to 
block complement mediated lysis of sheep erythrocytes in vitro (57).   VCP prevents 
complement-mediated neutralization of virus particles (50), and some anti-VCP 
antibodies can prevent this from occurring (48).  In vivo, VCP is a virulence factor; it is 
not necessary for replication, but knockout viruses are attenuated.  This was first shown 
in rabbit and guinea pig models, where a VCP-knockout (ko) virus made smaller lesions 
than wild-type virus (50).  VCP-ko viruses are also attenuated in a mouse intradermal 
model of infection.  This attenuation was linked to an increase in the hosts’ adaptive 
immune response (37). 
 
Other poxvirus complement control proteins 
 The vaccinia complement control protein has homologs in many other 
orthopoxviruses.  Proteins that have been characterized include the smallpox inhibitor of 
complement enzymes (SPICE), MoPICE from monkeypox virus, EMICE from 
ectromelia virus, and inflammation modulatory protein (IMP) from cowpox virus.  These 
proteins share a very high level of amino acid similarity with VCP, with up to 95% 
homology.  The small differences between these proteins has been used to learn about the 
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structure/function relationships in poxvirus complement inhibitors, and also about 
poxvirus evolution. 
 One of the closest homologs to VCP is SPICE, from smallpox.  It contains the 
same four SCR domains as VCP (74) and differs in only 11 amino acids (98).  
Intriguingly, these changes have a large effect on the functional profile of SPICE.  VCP 
has activity against a wide range of host complement proteins, but SPICE is a specialist.  
While less effective than VCP against most species’ complement systems, against human 
complement it has a much higher activity than VCP (98, 107, 142).  Electrostatic 
modeling has shown that the charge is markedly different between VCP and SPICE.  
VCP has a moderate positive charge in SCR1, and a net negative charge in SCR2 and 3.  
SPICE, in contrast, has a large positive charge in SCR1 and almost no charge in SCRs 2 
and 3 (107).  These changes may account for some of the functional difference between 
the two proteins.  Substitution mutagenesis has begun to shed light on the specific 
residues responsible.  The four changes H98Y, S103Y, E108K and E120K seem to be 
most important in conferring the highly human-active and human-specific profile of 
SPICE (107, 142).  Another mutated VCP with only two changes (Q77H and E120K) 
also had a regulatory profile similar to SPICE (69).   In addition to being secreted, 
recombinant SPICE can also be attached to the cell surface by binding to host 
glycosaminoglycans.  It does this through a series of heparin binding sites found on the 
protein (69).  On the surface of infected cells, it retains its ability to cleave C4b and also 
prevents the deposition of C3 (67). 
 The monkeypox homolog to VCP, MoPICE, is interesting in several respects.  
While there are two main strains of monkeypox, West and Central African, only Central 
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African isolates possess the ORF for MoPICE (19).  Central African strains are also more 
virulent and the presence of MoPICE has been proposed as one of the reasons for this 
difference (19).  The MoPICE ORF also encodes a protein that is shorter than the ones 
that encode VCP and SPICE due to an early stop codon in the fourth SCR domain.  This 
results in a truncated protein that expresses only the first three SCRs.  Despite the 
truncation it maintains the ability to bind C3 and C4 and has cofactor activity in vitro; 
however, there is no measurable decay-accelerating activity (68).  Interestingly, this 
truncation results in a free C-terminal cysteine.  MoPICE molecule form homodimers via 
this cysteine; the N-terminal residue in MoPICE is a tyrosine.      
EMICE is the ectromelia (mousepox) virus version of VCP.  It has been shown to 
protect MV particles from complement neutralization and infected cells from the 
alternative pathway of complement activation (85).  It can be expressed on the surface of 
cells through both an interaction with ectromelia A56 (24) and recombinant protein has 
been shown to bind cells through host glycosaminoglycans (85).   
The cowpox virus homolog of VCP is known as IMP, the inflammation 
modulatory protein.   In contrast to in vivo work with VACV lacking expression of VCP, 
cowpox viruses lacking IMP are more virulent in mouse models, due to increased 
inflammation and immune cell infiltration (45, 58).  This is different than with other 
PICES, which are either thought to be or have been shown to contribute to poxvirus 
virulence in vivo.  These results may be a result of the specific model; however, it does 
show that poxvirus inhibitors of complement have an effect on the host’s immune system.  
While most of the previous work studied PICES as secreted proteins, in the next chapters 
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we will investigate the mechanism and consequences of VCP and other PICE surface 
expression.   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Abstract 
The vaccinia virus A56 protein was one of the earliest described poxvirus proteins with 
an identifiable activity.  While originally characterized as a hemagglutinin protein, A56 
has other functions as well.  A56 is capable of binding two viral proteins, a serine 
protease inhibitor (K2) and the vaccinia virus complement control protein (VCP), and 
anchoring them to the surface of infected cells.  This is important; while both proteins 
have biologically relevant functions at the cell surface, neither one can locate there on its 
own.  The A56/K2 complex reduces the amount of virus from superinfecting an infected 
cell and also prevents syncytia formation of infected cells; the A56/VCP complex can 
protect infected cells from complement attack.  A56R is a non-essential gene and can be 
used as an insertion point for foreign genes and has been deleted in some viruses in 
clinical development as oncolytic agents.  Deletion of the A56R gene results in varying 
affects on vaccinia virus virulence, which are strain and infection model dependent.  
 
Introduction 
Orthopoxviruses are some of the most complex viruses infecting humans and 
include variola virus, the causative agent of smallpox, and vaccinia virus, which is used 
as a live-virus vaccine.  Although smallpox has been eradicated, vaccinia virus (VACV) 
is still studied as a model organism to understand basic aspects of poxvirology and as a 
vaccine-vector to immunize against infectious agents and as a candidate oncolytic agent.  
While VACV is a relatively large virus, the genome is still small compared to host cells.  
For this reason, VACV encodes a number of multi-functional proteins, one of which is 
A56. 
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There is a long history of studies with VACV looking at what is now called the 
A56 protein, which is found on the membrane of infected cells and some virus particles 
(Fig. 2.1).  Because of its hemagglutination activity, the protein was one of the first 
VACV proteins identified and studied (87) and was called VACV hemagglutinin (HA) 
from the 1940s until near the end of the 20th century.  The presence of a VACV protein 
with hemagglutination activity was believed to be important because several other viruses 
such as influenza, measles, and mumps contained proteins with hemagglutination 
activity.  The VACV protein responsible for this activity was first isolated in 1977 (46). 
  The ability to track the protein by hemabsorption provided a means to show that it 
was on the infected-cell membrane (11) and not on mature virus (MV) (Fig. 2-1).  HA 
was also found on extracellular virus (EV) (94).  While a biologically relevant function 
could not be ascribed to VACV’s hemagglutination activity, in the course of studying 
HA, many important discoveries were made like the identity and location of the HA gene 
(108) and the apparent size of HA as an 85-kDa glycoprotein (111).  The A56 gene has 
two separate promoters for early and late gene expression.  Interestingly, late expression 
produces a smaller, 68-kDa form of A56 (14), although whether this form has biological 
significance is not known.  Both the 85 and 68-kDa forms of A56 can be seen via western 
blot at late times.  Based on the sequence, A56 contains putative sites for N- and O-
glycosylation (14, 90, 111).  When glycosylation is inhibited, A56 migrates at a weight of 
58-kDa, which is different than the 35-kDa calculated weight (110).  Much of this work 
has been summarized in a review by Hisatoshi Shida (109). 
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Fig. 2.1.  Diagram of the location of A56 in a VACV-infected cell.  A56, K2, and VCP 
have signal sequences that result in their insertion into the lumen of the endoplasmic 
reticulum (ER), where presumably initial protein-protein interactions take place, followed 
by trafficking through the secretory pathway.  As a transmembrane protein, A56 is found 
on the infected cell surface, where it is present as a monomer, as well as in complex with 
K2 and VCP.  A56/K2 (and possibly A56/VCP) is also found on extracellular virus (EV).  
Also shown is the viral factory producing mature virus (MV). 
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A schematic diagram of A56 is shown in Fig. 2.2.  The N-terminal region of A56 has 
homology with the immunoglobulin (Ig) superfamily.  In this Ig-domain, it was 
hypothesized that the two cysteines form an intramolecular disulfide bridge.  Computer  
modeling shows that the first two cysteines of A56 are in close proximity and are 
predicted to form an intramolecular bridge (Fig. 2.3).   Between the Ig-domain and the 
transmembrane domain are two tandem repeat motifs (51), which do not share homology 
to other proteins.  An intracellular domain of ~13 amino acids is present at the C-
terminus and may be responsible for trafficking A56 out of the ER and into the Golgi 
(113).  Analysis of mutants produced by chemical mutagenesis (113) revealed that the 
hemabsorption and the cell-cell fusion regulatory properties of A56 are separate (105).  
While gene knockout viruses cannot perform either function, one point mutant (Glu121 
to Lys) was found to be hemabsorption-negative, but could still prevent syncytia 
formation.  Similarly, a virus that contained a Cys103 mutation formed syncytia, but 
hemabsorption was unaffected.  This suggested that while both hemagglutination and 
syncytia-prevention functions can be traced to the Ig-domain, there are distinct residues 
that impact these functions. 
 
A56 inhibits spontaneous cell-cell fusion of VACV-infected cells by forming a 
complex with K2 
The ability to hemagglutinate was not the only early function ascribed to A56.  Cells 
infected with some VACVs can result in cell-cell fusion, and in 1971 this was directly 
linked to a lack of A56 (47).  Interestingly, the loss of another viral protein, K2, also 
causes infected cells to fuse (62, 127, 147).  A56 and K2 was found to form a complex on  
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Fig. 2.2:  Schematic map of the domains of A56.  After a cleaved signal sequence 
(residues 1-19), there is an Ig-domain (residues 20-120), which includes a predicted 
intramolecular disulfide bridge (cysteines 34 and 103), a stalk region (121-275) 
containing tandem repeats (170-240), a transmembrane domain (276-303), and a 
cytoplasmic tail (residues 304-315).  K2 binding appears to occur with the Ig-domain; 
cysteine 162 forms a disulfide bridge with a free cysteine on VCP.  Also shown are 
locations of the predicted N-linked glycoslyation sites (lollipops) at residue 37, 69, 112, 
161, and 254. 
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Fig. 2.3:  Predicted structure of the N-terminus of A56.  Homology modeling of the 
Ig-domain of A56 predicts a disulfide bridge between cysteine residues shown as spheres.  
The N-terminal domain of A56 was used as a query sequence for five iterations of PSI-
BLAST (3) searching of the NCBI RefSeq database (96).  The best scoring protein from 
this query with an atomic structure is the T-cell receptor alpha chain IgG domain from 
Cf34 (PDB 3FFC, Chain D (39)), with an E score of 9.02e-27 and 22% sequence identity.  
The A56 sequence was threaded onto this three-dimensional structure using the 
homology modeling program MODELLER 9v8 (29).  The model was rendered using the 
program PYMOL. 
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the surface of infected cells, and that this complex is responsible for preventing syncytia 
(125).  K2 is also found on EV particles, as observed by electron microscopy and 
proteomics (15, 71).  K2, also known as serine protease inhibitor (SPI)-3, is one of a 
family of poxvirus proteins with homology to serpin proteins (13).  K2 (SPI-3) has in 
vitro protease-inhibition activity (124, 136), but this activity is not required to prevent 
syncytia (126). 
The mechanism by which the A56/K2 complex inhibits spontaneous fusion of 
infected cells was not clear until the discovery that the virus-encoded multi-subunit entry 
fusion complex (EFC) found on the MV membrane (106) interacted with the A56/K2 
complex (131).  A56/K2 interacts with A16 and G9 proteins, two proteins that are part of 
the EFC (133).  These findings led to the hypothesis that A56/K2 on infected cells could 
prevent re-infection of already infected cells.  Support for this was obtained when 
VACVs with deletions of A56 or K2 were used to infect cells followed by superinfection 
with VACV with a luciferase reporter gene.  Superinfection of cells that were infected 
with virus expressing A56/K2 had significantly lower luciferase levels than cells infected 
with a virus expressing a mutated A56/K2 (128).  Also, transfecting A56 and K2 into 
cells is sufficient to diminish both infection and cell-cell fusion (132).  The A56/K2 
complex preventing superinfection by incoming MV particles should not be confused 
with the ability of another set of poxvirus proteins (A33 and A36) that can repel EV, a 
process that speeds up viral spread (25). 
 
III. Cell surface expression of VCP through interactions with A56 
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K2 is not the only viral protein that directly interacts with A56.  A new interaction 
was recently discovered between A56 and VCP.  VCP is a 35-kDa protein that was 
previously characterized as the major secreted protein from VACV-infected cells (50, 57, 
59).  VCP has the ability to inhibit complement activation (e.g., (9, 57, 68, 69, 76, 80, 86, 
97, 98, 100, 107)).  VCP-deletion viruses are mildly attenuated in vivo (24, 50), possibly 
due to an improved adaptive immune response in the absence of complement inhibition 
(37).  Besides being secreted, VCP is expressed on the infected cell surface (36).  Surface 
expression required the presence of A56 and the free N-terminal cysteine on VCP (36).  
Furthermore, this free cysteine on VCP forms a covalent bond with the cysteine 162 on 
A56 (24).  The A56/VCP complex can protect infected cells from complement-mediated 
lysis (24, 36), and surface-bound VCP may be important for full virulence in vivo (24, 
36). 
The interaction between VCP and A56 is not limited to VACV.  The smallpox 
homolog of VCP can also bind to VACV-A56 when plasmids expressing both proteins 
are transfected into cells.  Also, immunofluorescence staining of ECTV-infected cells 
shows surface expression of its complement control protein (CCP).  Interestingly, in 
transfection studies, ECTV-CCP does not interact with VACV-A56, but is able to bind 
ECTV-A56 (24).  This suggests co-evolution of these proteins may have occurred.  The 
monkeypox virus (MPXV) CCP does not contain a free N-terminal cysteine; however, 
due to a mutation that results in early termination, there is an unpaired C-terminal 
cysteine.  While this C-terminal cysteine allows MPXV-CCP to form disulfide-bonded 
homodimers (68), it appears not to allow efficient interaction with MPXV-A56 for 
surface expression (24).  By transient tansfection and immunofluorescent staining of 
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MPXV-infected cells, some MPXV-CCP surface staining is seen, but at a much lower 
level than seen with the other poxvirus CCPs (24).  Proteomics on MV and EV particles 
from VACV and MPXV found VCP on VACV virions, and that more VCP was found on 
EV than MV (71).  Conversely, MPXV virions had no MPXV-CCP (71).  This is 
consistent with the finding that VCP, but not MPXV-CCP, binds to A56 efficiently and 
also likely suggests the presence of A56/VCP on EV particles (Fig. 2.1).  Much of the 
work summarized in this section will be explained in greater detail in chapters 3,4 and 5 
of this thesis. 
 
A56 and VACV virulence 
 The contributions of A56 to VACV virulence have not been fully elucidated.  
Virulence levels appear to vary widely according to the route of infection and the strain 
of the parental virus.  Work with the NYCBH strain showed significant attenuation with 
an A56R gene knockout (ko) virus (64).  Intracranially, the A56R-ko had an LD50 of 
1.6×105 pfu versus 1.9×102 pfu for the wildtype virus.  Intranasally, the difference was 
even more pronounced, with and an LD50 of A56R-ko of >1×108 pfu versus 2.5×104 pfu 
for the wildtype virus.  This degree of attenuation was not as clear with other strains of 
VACV.  In studies with a Lister-based oncolytic virus containing directed deletions of the 
thymidine kinase (J2L) and F14.5 genes, the addition of an A56R deletion resulted in 
evidence of further attenuation.  Infection of nude mice with the parental J2L/F14.5-
deletion virus resulted in survival of >100 days, but all mice eventually died by day 120.  
Mice infected with the virus with the additional A56R-ko survived for the length of the 
study, 135 days (145, 146).  However, the mice in this experiment had xenograft tumor 
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implants, making it difficult to ascertain whether death was from tumor growth or viral 
replication.  An A56-ko in VACV strain Western Reserve (WR) showed a small amount 
of attenuation when given intracranially in young mice (31).  In this model, mice infected 
with an A56R-ko died more slowly (first death at five days, last death at 17 days) than 
with a wildtype virus (100% death at 8 days).  No attenuation was seen when inserting a 
foreign gene in the place of A56R in the LC16mO or LO strains when given by either 
intracranial or intraperitoneal routes (112). 
 Deletion of the VACV proteins that bind A56 results in different levels of in vivo 
consequence.  K2-deletions in strain WR do not appear to be attenuated, with no 
difference in survival after intranasal infection (62).  Similarly, intranasal infection of 
mice with a K2-ko cowpox or wildtype viruses had nearly identical LD50s (5.3 × 105 pfu 
and 5.1 × 105 pfu, respectively) (119).  As previously mentioned, VCP is needed for full 
VACV (strain WR) virulence, as VCP-ko are attenuated when given intradermally to 
rabbits and guinea pigs (50), and when given to mice intradermally or intranasally (24, 
37).  The specific contribution of surface expression of VCP to virulence is not yet 
known. 
 
Other uses of A56 
Because A56R is a non-essential gene for VACV replication, it has been used as a 
region in the genome for insertion of foreign genes.  The hemagglutinin properties of 
A56 allow for identification of recombinant plaques with foreign genes inserted into 
A56R in the absence of a selection marker.  That is, the addition of chicken erythrocytes 
to an infected cell monolayer will cause wildtype plaques to appear red, while 
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recombinants with deletion of A56R will remain white (89, 113).  Another application of 
A56 mutants has been in the development of VACV as an oncolytic agent.  GLV-1h68, 
which includes the deletion of A56R along with a series of other gene deletions, was able 
to reduce the size of breast cancer tumors in a nude mouse model (146).  This virus has 
since been successfully used to shrink tumors in several other xenograft mouse models 
(35, 66, 139, 143, 144). 
 
Conclusions 
The history of A56 can be divided into two acts.  In the first act, HA was 
discovered and many basic characteristics were described.  After a number of years of 
diminished work, the last decade has seen a burst of studies that focus on A56.  During 
this second act, A56 interactions with other viral proteins and their relevant biological 
functions were discovered.  A56 is found in multiple locations during an infection (Fig. 
2.1), and its interactions with other viral proteins produce multiple effects.  While A56 is 
a “non-essential” protein, it is an important one: through its interaction with K2 it is 
involved in preventing re-infection of already infected cells, which may promote viral 
spread.  Through its interactions with VCP, it is involved with defending infected cells 
from the host’s immune response.  Research on A56 has also been incorporated into new 
oncolytic agents and new panels of mutant viruses are in progress that may further 
elucidate the role A56 plays in pathogenesis.  
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Abstract 
The vaccinia virus complement control protein was originally characterized as the major 
protein secreted from infected cells.  Although it lacks a transmembrane domain, we 
observed that VCP is also expressed on the surface of infected cells.   In order to 
characterize this finding, we studied a panel of recombinant viruses that produced tagged 
and/or mutated versions of VCP.  We found that VCP co-purifies with the viral protein 
A56, a transmembrane protein found at the cell surface.  We also confirmed that the N-
terminal free cysteine is critical for surface expression of VCP, and that this expression 
occurs even if only the first 85 amino acids (19 a.a. signal peptide + 66 residues) are 
present. 
 
Introduction 
Vaccinia virus (VACV) encodes many non-essential proteins, some of which can 
be characterized as virulence factors that affect pathogenesis (40, 104).  One of these is 
VCP, the vaccinia complement control protein.  VCP shares homology to host regulators 
of complement, and is made up of short consensus repeat (SCR) domains (59).  It is able 
to block activation of complement at multiple steps (57, 76, 86, 100), preventing 
complement-mediated virus neutralization (50) and affecting both innate and adaptive 
immune responses (37).   
VCP has been well characterized as the major secreted protein from VACV-
infected cells (59), and important for full virulence in vivo in multiple animal models (24, 
37, 50).  Our lab made the observation that VCP is also expressed on the surface of 
infected cells.  Since some host complement regulatory proteins are active on the cell 
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surface, we hypothesized that surface expression of VCP may have functional 
consequences.  VCP lacks a transmembrane domain or any described binding partners, so 
we were interested in whether VCP bound to any viral or cellular proteins at the cell 
surface.  Prior research in our lab showed two important findings:  first, that the free N-
terminal cysteine of VCP is critical for cell surface expression, and that the viral protein 
A56 is also required for surface expression (36).  Cells infected with recombinant 
VACVs with the free cysteine of VCP mutated to a threonine (vvVCPmut) or a virus 
lacking A56 (vvA56-ko) still produce VCP, but cannot express it on the cell surface (36).  
A56 is an Ig-like protein that has a transmembrane domain (51); it interacts with another 
vaccinia protein called K2 at the surface of infected cells (125). 
To investigate VCP surface expression, we used two sets of viruses.  The first set 
consists of adding a His-tag to both wild-type and the cysteine-mutated VCP.  The 
second set consists of truncated VCP proteins, where only the first SCR domain is 
present.  Here, we demonstrate that VCP forms a high-molecular weight complex with 
the viral A56 protein by both native Western blotting of infected cell lysates and also 
affinity pulldown analysis.  We also show that only the first SCR of VCP is required for 
this interaction.  These viruses furthered our understanding of the mechanism of VCP cell 
surface expression, and the relationship between VCP and A56.   
 
Methods 
Virus construction 
vv-VCPwt-His (vv91i) and vv-VCPmut-His (vv205a1-1) were designed to overexpress 
His-tagged forms of VCPwt and VCPmut, respectively. The viruses were generated by 
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homologous recombination of plasmid constructs into the parental virus vSIGK-1 (57). 
This parental virus has a gpt selection cassette replacing the entire VCP ORF (as well as a 
portion of the flanking regions). His-tagged forms of VCP under the control of a VACV 
synthetic strong early-late promoter (18) were then inserted into the thymidine kinase 
locus, and recombinant viruses were isolated by selection with bromodeoxyuridine and 
screening with β-galactosidase. After three rounds of plaque purification, isolated plaques 
were expanded and the sequences of the recombinant viruses were confirmed using PCR 
and Western blotting. The plasmids used for homologous recombination were 
constructed by adding a 6×-His tag to the carboxy terminus of the VCP ORF using PCR 
primers to make VCPwt-His (36) and by cloning this PCR product into pSC65 (18).  The 
resulting plasmid also served as the template to generate a His-tagged VCP containing 
the cysteine-to-threonine mutation. This mutation was introduced using QuikChange site-
directed mutagenesis (Stratagene) with the same primers used in the generation of for vv-
VCPmut (36). The plasmid was sequenced to confirm the mutation and to ensure that no 
other unintended mutations were generated during PCR amplification.  Also used in these 
studies are the previously constructed viruses vvVCP-SCR1 (original name v200b2-1), 
vvVCPmut-SCR1(v210k2-1),  vvVCP-SCR1+cys (v183b2-1) and vvVCPmut-SCR1+cys 
(v184m3-1).  These viruses were generated from the VCP-knockout virus vSIGK-3, 
which contains a gpt selection cassette interrupting the VCP open reading frame.  The 
plasmid pGK35 (57) contains a truncated VCP ORF under the natural VCP promoter and 
expresses the first SCR followed by 5 amino acids before a frame shift mutation results in 
a stop codon.  This plasmid was used along with parental virus vSIGK3 to generate 
vvVCP-SCR1+ cys.  To make vvVCP-SCR1, site directed mutagenesis was used to place 
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a stop codon before the C-terminal cysteine (primers used were: for: 5`--CTC TTT AAT 
CAA TGT ATT AAA TAA TGA TGC CCA TCG CCT CGA G—3`; rev: 5`-C TCG 
AGG CGA TGG GCA TCA TTA TTT AAT ACA TTG ATT AAA GAG—3`).  The 
resulting plasmid was called pTM234.  For vvVCPmut-SCR1+cys and vvVCPmut-
SCR1, the previously described N-terminal Cys to Thr primer set was used to mutate 
pGK35 and pTM234, respectively.  After infection with vSIGK3 and tranfection with 
these newly constructed plasmids, viruses were plaque purified by reverse gpt selection 
(49). 
 
Immunofluorescence 
RK-13 cells were infected at an MOI of 1 with indicated viruses in 8-well chamber slides.  
At 24 hours post-infection, media was removed and the cells were washed with PBS and 
then fixed with 1% paraformaldehyde.  To permeablize the cells, cells were incubated 
with 0.1% Triton X-100.  After blocking in 1% BSA, the primary antibody (the anti-VCP 
monoclonal 3B1 (48)) was added at 10 µg/ml for one hour at room temperature.  After 
three washes with PBS, a FITC anti-mouse secondary antibody was added at a dilution of 
1:5000 for another hour.  After three more washes with PBS, DAPI was added to the cells 
and a coverslip was mounted for viewing.   
 
Western blotting  
For nonreducing, nondenaturing (native) gels, cells were infected in 2.5% MEM and cell 
lysates were harvested as described above and lysed in RIPA buffer (1% Triton X-100, 
150 mM NaCl, 50 mM Tris) containing 1× protease inhibitor (Sigma). Native samples 
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were diluted in sample buffer containing 0.1% SDS and no reducing agents without 
boiling, and proteins were resolved on a 10% Tris-glycine gel and Western blotted for 
VCP using the mouse anti-VCP MAb 3F11 (48) at a concentration of 5 µg/ml.  For 
reducing and denaturing gels samples were diluted in sample buffer containing 1.0% SDS 
+ beta-mercaptoethanol, boiled and resolved on a 10% Tris-glycine gel; membranes were 
probed for VCP using the mouse anti-VCP MAb 5F1 (48) at a concentration of 5 µg/ml 
in blocking buffer for 2 h at room temperature. . After being washed with PBS containing 
0.02% Tween 20, horseradish peroxidase-conjugated goat anti-mouse secondary antibody 
(Santa Cruz) was diluted 1:2,000 in blocking buffer and incubated with the membranes 
for 2 h. The membranes were then washed, and proteins were detected by 
chemiluminescence using the enhanced-chemiluminescence Western blotting detection 
kit (GE Healthcare Biosciences). Blots were imaged using an LAS-1000 Pus gel 
documentation system (Fujifilm). 
 
A56 pulldown 
BSC-1 cells in T-75 flasks were infected in 2.5% MEM at an MOI of 1 for 48 h. Cells 
were harvested, washed once in ice-cold buffer (50 mM Tris-HCl [pH 7.4] and 150 mM 
NaCl), and lysed in lysis buffer (50 mM Tris-HCl [pH 7.4], 1% Triton X-100, 150 mM 
NaCl, and 1× protease inhibitor cocktail [Sigma]). Cells lysates were clarified by 
centrifugation and incubated with nickel-agarose beads for 2 h at 4°C. Samples were 
loaded onto a column, washed three times with lysis buffer containing 20 mM imidazole, 
and bound proteins were eluted with lysis buffer containing 500 mM imidazole. Proteins 
eluted from the column were separated by SDS-polyacrylamide gel electrophoresis 
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(PAGE) under reducing and denaturing conditions and transferred to nitrocellulose. 
Membranes were probed for His-tagged VCP and for A56. To probe for His-tagged VCP, 
membranes were incubated with a primary anti-6x-His tag MAb (Qiagen) diluted 1:200. 
The membrane was then washed and incubated with a horseradish peroxidase-conjugated 
secondary goat anti-mouse IgG antibody diluted 1:3,000 (Santa Cruz). Membranes were 
also probed for A56 using polyclonal rabbit anti-A56 peptide antiserum (131) diluted 
1:1,250. The membranes were then washed and incubated with a secondary donkey anti-
rabbit antibody conjugated to horseradish peroxidase (GE Healthcare Biosciences). 
Proteins were detected with SuperSignal West Pico chemiluminescence reagent and 
imaged using an LAS-1000 Pus gel documentation system (Fujifilm). 
 
Results 
Characterization of a high molecular weight complex containing VCP 
Previous data suggested that A56 is necessary for the localization of VCP to the 
cell surface (36); we hypothesized that there is a specific interaction between VCP and 
A56. When lysates from cells infected with vv-VCPwt were resolved under nonreducing, 
nondenaturing (native) conditions and probed for VCP, three distinct bands were present 
(Fig. 3.1, first lane). These bands include an ~30-kDa band representing the VCP 
monomer, an ~50-kDa band representing the VCP dimer, and a third high-molecular-
mass band. The presence of the high-molecular-mass band suggests that VCP interacts 
with another protein. To determine if A56 was required for the formation of the high-
molecular-mass complex, lysate from cells infected with vv-A56ko was resolved under 
native conditions and probed for VCP (Fig. 3.1, third lane). In the absence of A56, we 
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found the ~30-kDa and ~50-kDa bands, representing monomeric VCP and dimeric VCP, 
respectively, but the high-molecular-mass band was no longer present.  This suggests that 
the high-molecular-mass complex does not form in the absence of A56. Furthermore, 
when lysates from cells infected with vv-VCPmut were probed for VCP, only monomeric 
VCP was detected, demonstrating the importance of the unpaired cysteine residue on 
VCP for dimer formation, as well as the formation of the higher-molecular-mass complex 
(Fig. 3.1, second lane). 
 
His-tagged VCP is still expressed at the surface of infected cells 
 In order to generate reagents to show a physical interaction between A56 and 
VCP, we created two tagged VCP-producing viruses: vvVCP-His and vvVCPmut-His.  
Both of these contain C-terminal 6x Histidine tags, as diagrammed in Figure 3.2A.  In 
order to see if tagging VCP interferes with surface expression, infected cells were 
prepared for immmunofluorescence staining with an anti-VCP antibody.  Under 
permeablized conditions, both VCP-His and VCPmut-His are produced and can be seen 
intracellularly in permealblized cells.  Importantly, under non-permeablized conditions 
VCP-His, but not VCPmut-His is seen at the cell surface (Fig 3.2B).  This mirrors what is 
seen with un-tagged proteins, and shows that the His-tag does not alter cell-surface 
expression.   
 
VCP interacts directly with A56 
To determine if VCP and A56 interact in infected cells, we used viruses encoding His-
tagged forms of VCP (vv-VCPwt-His) or VCPmut (vv-VCPmut-His) to pull down A56.  
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Fig. 3.1: VCP forms a high weight complex under native conditions. (A) BSC-1 cells 
were infected overnight with the indicated virus at an MOI of 5. Infected cells were then 
harvested and washed with and lysed in RIPA buffer. Lysates were run on a 10% precast 
gel under native (nonreducing, nondenaturing) conditions. Membranes were transferred 
to nitrocellulose and probed for VCP using MAb 5F1. 
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 Lysates from cells infected with vv-VCPwt-His or vv-VCPmut-His incubated 
with nickel-agarose. Following extensive washing, proteins were eluted with imidazole, 
separated using SDS-PAGE, and probed for A56 (Fig. 3.3). We found that A56 was 
present only in eluates from vv-VCPwt-His-infected cells, not vv-VCPmut-His-infected 
cells, indicating that A56 interacts with vv-VCPwt-His but not vv-VCPmut-His. Taken 
together, these results indicate that VCP and A56 interact in infected cells. Of note, at the 
same time we were performing this work, Wagenaar and Moss used tandem affinity 
purification and mass spectrometry to identify proteins that interact with A56 (131). 
Their study identified VCP as one of many proteins that copurifies with A56, lending 
support to our finding that these two proteins interact. 
 
Truncated forms of VCP are expressed on the cell surface (unpublished data) 
 The N-terminal cysteine of VCP has been established as critical for cell-surface 
expression of VCP and presumably interacting with A56 (36).  However, it was initially 
unknown what other parts of the protein may play a role in this interaction.  A 
previously-made mutant virus, vvSIGK-8 (49), was able to shed some light on this 
question.  vvSIGK-8 was previously isolated by Stuart Isaacs and Girish Kotwal from 
vSIGK-3, a recombinant virus that had a gpt cassette inserted within a 70 base pair 
deletion within VCP.  The removal of the gpt cassette from vvSIGK-3 resulted in 
vvSIGK-8, a virus that still did not express a full length VCP protein.  However, on 
closer inspection, the removal of the gpt cassette resulted in an ORF that expressed 70 
amino acids (SCR1 plus a few residues of SCR2). Antibodies that recognized the first 
SCR revealed that this fragment of VCP was found to be both secreted from cells (48)  
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Fig. 3.2:  His-tagged VCP is still expressed at the cell surface.  (A) Schematic diagram 
of wild-type VCP tagged with a 6x-His tag; also shown is VCPmut (Cys20Thr) with the 
same tag.  (B) Immunofluorescence of infected RK-13 cells under either permeablized 
(P; for internal staining) or non-permeablized (NP; for cell-surface staining only) 
conditions.  VCP is stained green, and the cell nuclei are stained blue with DAPI.   
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Fig. 3.3:  VCP and A56 interact under native conditions. BSC-1 cells were infected 
for 48 h with the indicated viruses expressing His-tagged versions of VCP at an MOI of 
5. Lysates were incubated with nickel-agarose. Proteins were eluted with imidazole, 
separated via SDS-PAGE under reducing, denaturing conditions; and probed for the 
presence of A56 using an anti-A56 rabbit polyclonal antibody (top) or probed for VCP 
using an anti-His antibody (bottom). Molecular mass markers (in kDa) are indicated 
along the left-hand side of the gels. α, anti. 
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and on the cell surface (Isaacs, unpublished).  However, because of the way the mutation 
in vSIGK-8 was made, the expressed first SCR also contained a C-terminal cysteine (a 
remnant of the beginning of the second SCR) and thus it was not clear if surface 
expression was due to the abnormal expression of a protein with both a N- and C-
terminal cysteine (Fig 3-4A, vvVCP-SCR1+cys, a virus that was re-generated similar to 
vSIGK-8).  To further investigate this, we made additional VCP mutants, each containing  
only the first SCR either of the wild-type protein (vvVCP-SCR1) or VCPmut 
(vvVCPmut-SCR1) (Fig. 3.4A).  Interestingly, we found that VCP-SCR1 is still 
expressed on cell surface, while vvVCPmut-SCR1 was not.  This means that only the N-
terminal ~60 amino acid residues are necessary for the VCP/A56 interaction to occur. We 
also recreated the original truncated VCP from vvSIGK-8.  This virus is called VCP-
SCR1+cys, as the extra residues from SCR2 results in an additional C-terminal free 
cysteine (Fig 3.4A).  As with the original virus, this form of VCP is expressed on the cell 
surface (Fig 3-4B, vvVCP-SCR1+cys).  Mutating the N-terminal cysteine of this 
truncated VCP yielded surprising results.  When this residue is mutated to a threonine in 
this protein, cell surface expression remains, presumably through the unpaired C-terminal 
cysteine (Fig. 4a and b, vvVCPmut-SCRcys).  In contrast, mutating the N-terminal 
cysteine from VCP-SCR1 (VCPmut-SCR1) abrogates surface expression (Fig. 3.4B, 5th 
panel), because this truncated form of VCP has no unpaired cysteines.  This also 
reinforces the idea that only the first SCR and a free cysteine are necessary for this 
interaction.   
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Fig. 3.4:  Analysis of truncated VCP proteins’ surface expression. (A) Schematic of 
four different truncated VCP proteins. vvVCP-SCR1+cys has N- and C-terminal 
cysteines; vvVCPmut-SCR1+cys has the C-terminal unpaired cysteine.  vvVCP-SCR1 
only contains the original N-terminal free cysteine, while vvVCPmut-SCR1 has none.  
(B) Immunofluorescence of infected cells. RK-13 cells were infected with the indicated 
viruses for 24 hours and stained for VCP under non-permeablized (NP) conditions. 
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Discussion 
The vaccinia complement control protein has already been well described as a virulence 
factor that is secreted from infected cells (50, 57).  Here, we have begun to characterize 
VCP as a protein that is also expressed on the cell surface and also started to uncover the 
mechanism of surface expression.  We have discovered that VCP binds to A56, a 
vaccinia protein that possesses a transmembrane domain.  This relationship has also been 
shown between A56 and a viral protein before, with K2, also known as serine protease 
inhibitor 3 (SPI-3).  K2 is a soluble viral protein that cannot localize to the cell surface on 
its own.  A56 binds K2 non-covalently (125), forming a complex that prevents syncytia 
formation and viral superinfection (125, 128, 131, 132).  Since complement can act at the 
cell surface, it is possible that surface-bound VCP has a biological function there that has 
implications in pathogenesis.   
Work presented here and elsewhere has established that the N-terminal free 
cysteine of VCP is necessary for stable interaction with A56, and therefore cell-surface 
expression.  We also showed that only the first SCR of VCP is necessary for surface 
expression, meaning that the critical interaction residues are located in that region.  Two 
different hypotheses for this mechanism of the interaction and cell-surface expression can 
be proposed.  The first is that a cysteine-bridged VCP dimer formation is necessary for 
VCP to bind non-covalently to A56. The second is that an intermolecular disulfide bridge 
forms between VCP and A56. This is possible because the ectodomain of the A56 protein 
has three cysteines.  As A56 has an Ig domain, two of cysteines are predicted to form an 
intramolecular disulfide bridge.  The third cysteine has no described function, and so may 
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allow the formation of an intermolecular disulfide bond with VCP.  In the next chapter 
we will describe a series of experiments with A56 mutants and their ability to bind to 
poxvirus complement control proteins. 
Our findings with vvVCP-SCR1 and vvVCPmut-SCR1cys (Fig. 3.4A) are also 
tantalizing.  It suggests that if the first SCR is available to interact with A56, then a free 
cysteine, not necessarily the N-terminal cysteine, is all that is needed for cell surface 
expression (Fig. 3.4B).  In addition, this piece of data can be used to argue against the 
hypothesis that a VCP dimer binds to A56 since if vvVCPmut-SCR1cys expresses a 
protein that forms homodimers, the first SCR would be in a tail-to-tail conformation 
instead of a head-to-head conformation.  It is unlikely that the first SCRs of VCP would 
form the same binding conformation when they are attached by C-terminal cysteines and 
when they are bound as a dimer by their N-terminal cysteines.  But equally perplexing is 
that an initial interaction between A56 and VCP can occur with either an N- or C- 
terminal free cysteine on SCR1.  Further work involving mutagenesis of A56 will provide 
answers whether A56 and VCP form an intermolecular disulfide bond, and in vivo work 
with mutated and knockout viruses may find a role for surface-bound VCP in vaccinia 
pathogenesis and virulence. 
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Abstract 
The vaccinia virus (VACV) complement control protein (VCP) is an immunomodulatory 
protein that is both secreted from and expressed on the surface of infected cells.  Surface 
expression of VCP occurs though an interaction with the viral transmembrane protein 
A56, and is dependent on a free N-terminal cysteine of VCP.  Although A56 and VCP 
have been shown to interact in infected cells, the mechanism remains unclear.  To 
investigate if A56 is sufficient for surface expression, we transiently expressed VCP and 
A56 in eukaryotic cell lines, and found that they interact on the cell surface in the 
absence of other viral proteins.  Since A56 contains three extracellular cysteines, we 
hypothesized that one of the cysteines may be unpaired and could therefore form a 
disulfide bridge with VCP.  To test this, we generated a series of A56 mutants in which 
each cysteine was mutated to a serine, and found that mutation of cysteine 162 abrogated 
VCP cell surface expression.  We also tested the ability of other poxvirus complement 
control proteins to bind to VACV A56.  While the smallpox homolog of VCP is able to 
bind VACV A56, the ectromelia virus (ECTV) VCP homolog is only able to bind the 
ECTV homolog of A56, indicating that these proteins may have co-evolved.  Surface 
expression of poxvirus complement control proteins may have important implications in 
viral pathogenesis, as a virus that does not express cell surface VCP is attenuated in vivo.  
This suggests that surface expression of VCP may contribute to poxvirus pathogenesis. 
 
Introduction 
Poxviruses, including vaccinia virus (VACV), encode large numbers of 
immunomodulatory proteins that help them establish an infection and combat the host’s 
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immune response (40, 104).  One of these is the vaccinia complement control protein 
(VCP), which is both secreted from and expressed on the surface of infected cells (36, 50, 
57, 59).  VCP acts against the complement system, a series of soluble proteins that is an 
important early component of the innate immune system and also shapes adaptive 
immune responses (55, 134, 135).  In response to viral infection, complement can 
opsonize or inactivate virions and can lyse enveloped virus or infected cells (8, 12, 20, 
44).  Because of these pressures, a number of viruses, such as HSV, flaviviruses, and 
poxviruses encode novel or host-derived regulators of complement, while others such has 
HIV and poxviruses incorporate host complement regulatory proteins into virus particles 
(20, 42, 101, 130).  Many orthopoxviruses encode a complement regulator (21, 68, 80, 
98), and the most studied of these is VCP.  Structurally, VCP is made up of four short 
consensus repeats (SCR) that are the basic units of mammalian complement regulators 
(59, 86) and has been shown to interfere with the complement cascade at multiple steps 
(9, 57, 68, 69, 76, 86, 97, 98, 100, 107).  Additionally, a VCP knockout virus generates 
smaller lesions in animal models (50, 57).  While some host complement control proteins 
(CCPs) are secreted, many contain transmembrane domains (or a GPI anchor) and are 
thus expressed on the cell surface (134, 135).  Thus, when we found that VCP is also 
expressed on the infected cell surface and protected infected cells from complement 
mediated lysis in vitro (36), we believed this to be an important interaction that required 
further investigation.  We previously found that the N-terminal cysteine on VCP was 
needed for surface expression and that the VACV transmembrane protein, A56, was also 
required (36).  The vaccinia A56 protein is a type 1 transmembrane glycoprotein that is 
found on the surface of infected cells and on extracellular virus particles (14, 60, 91, 93, 
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125).  It interacts with another viral protein, K2 (62, 127, 147), which lacks a 
transmembrane domain and binds to A56 non-covalently (125).  The A56/K2 complex 
prevents syncytia formation between infected cells and superinfection by interacting with 
the vaccinia entry/fusion complex on virions (83, 128, 131, 132).  Here we provide 
evidence that the N-terminal cysteine on VCP forms an intermolecular disulfide bond 
with cysteine 162 on the ectodomain of A56.  We also demonstrate that similar 
interactions can occur with other poxvirus CCPs, as the smallpox and ectromelia 
homologs of VCP also exhibit A56-dependent surface expression. 
 
Methods 
Cells and viruses 
 BSC-1, 293T, and RK-13 cells were grown and maintained in Minimum Essential 
Media (MEM) supplemented with 10% Fetal Bovine Serum.  Viruses were grown and 
titered in BSC-1 in MEM with 2.5% FBS.  The generation and isolation of vaccinia virus 
(vv)-VCPko, -VCPmut, and -VCPwt from the parental stain WR has been described 
previously (36).  The VCPrescue virus was made by reinserting the VCP open reading 
frame (ORF) under its native promoter into the VCPko virus.  After the initial infection 
of cells with VCPko and transfection with a plasmid containing wild type VCP ORF, the 
progeny virus was amplified on BSC-1 cells, and the cell lysate was used to infect fresh 
RK-13 cells.  After 24 hours of infection these cells were stained for VCP  with the anti-
VCP mAb 3F11 and an anti-mouse APC  secondary Ab  under non-permeablized 
conditions and positive cells were collected through live cell sorting.  The resulting cells 
were lysed, the virus was plaque purified 3-times on BSC-1 cells, and a stock of virus 
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was grown and purified.  PCR confirmed proper insertion of the gene back into the C3L 
position and that no mutations occurred during PCR amplification or virus isolation.  
Expression of VCP in the rescued virus was confirmed by western and FACS analysis.  
 
Cloning of poxvirus genes into expression plasmids 
The previously generated plasmids containing the ORF of VCP and VCPmut (36), as 
well as SPICE, MoPICE and EMICE (68)  were used to insert the ORFs into pCAGGS.  
The VACV A56 ORF was PCR amplified from VACV (strain WR) and initially cloned 
into Topo 2.1 using the primers 5’-CGG GGT ACC ATG ACA CGA TTA CCA ATA 
CTT TTG -3’ and 5’-CGC GCG GCT ACG CTA GAC TTT GTT CT-3’.  This plasmid 
was then used to generate A56mut1, mut2 and mut3 by site directed mutagenesis using 
overlapping primers.  A56mut1 primers were 5’- GCA ACT CTA TCA TCT AAT CGA 
AAT AAT ACA AAT G-3’ and 5’- CAT TTG TAT TAT TTC GAT TAG ATG ATA 
GAG TTG C-3’; A56mut2 primers were 5’- GCC GGT ACT TAT GTA TCT GCA TTC 
TTT ATG ACA TC-3’ and 5’- GAT GTC ATA AAG AAT GCA GAT ACA TAA GTA 
CCG GC-3’; A56mut3 primers were 5’- GAT TAT ATA GAT AAT TCT AAT TCC 
TCG TCG GTA TTC G-3’ and 5’- CGA ATA CCG ACG AGG AAT TAG AAT TAT 
CTA TAT AAT C-3’.  A56mut1+2 was created by site directed mutagenesis of A56mut1 
using the primers for mut2.  All 4 mutated ORFS were then inserted into pCAGGS.  The 
ectromelia A56 homolog was PCR amplified from the ECTV Moscow strain (primers: 
5’- CGG GGT ACC ATG GCA CGA TTG TCA ATA CTT TTG-3’ and 5’- CGC GCG 
GCT AGC CTA GAC TTT GTT CTC TGT TTT G-3’) and the monkeypox A56 
homolog PCR amplified from MPXV-Zaire and cloned into Topo2.1 prior to insertion 
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into pCAGGS (forward primer: 5’- CGG GGT ACC ATG ACA CAA TTA CCA ATA 
CTT TTG-3’; reverse primer is the same as ECTV A56).  K2 was cloned from VACV 
(strain WR) with the addition of a C-terminal HA tag using the primers 5’- CGG GGT 
ACC ATG ATT GCG TTA TTG ATA CTA TCG-3’ and 5’- CGC CGA TCG TTA GGC 
ATA ATC GGG AAC ATC GTA GGG GTA AGA GCC ACC GCC ACC AGG AGA 
TTC CAC CTT ACC CAT AAA C-3’.  The ORFs in all final plasmids were sequenced 
to confirm sequences (or site directed point mutations) were correct. 
 
Transfection of poxvirus genes and flow cytometry 
 Plasmid transfections were performed in 6-well plates of 95% confluent 293T 
cells using Lipofectamine and serum-free media.  Two micrograms of each plasmid was 
used per well, along with 10 µl of Lipofectamine.  Forty-eight hours later, the cells were 
lifted in FACS buffer (PBS without Ca++/Mg++ with 1% FBS and 0.04% sodium azide) 
and transferred to FACS tubes.  Cells were then incubated with anti-VCP Ab (either a 
mouse monoclonal (mAb) 3F11 (48, 131) or a rabbit polyclonal (68)) and anti-A56 Ab 
(either mAb LC10 or a previously described peptide-raised rabbit polyclonal antibody 
(131)) at 1:1000 dilutions.  After washing, the cells were incubated with appropriate 
FITC and APC conjugated anti-mouse or anti-rabbit antibodies at a 1:40 dilution and then 
fixed using 3% PFA (paraformaldehyde).  The cells were then read on a FACScaliber and 
analyzed using FlowJo.  Scatter plots were gated on live cells using forward and side 
scatter.  Histograms were created by gating on cells that were A56 positive.  For the K2 
FACS, collected cells were incubated with the rabbit anti-A56 Ab and a previously 
described K2 mAb 4A11-4A3 (15). 
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Affinity isolation of tagged A56 from infected cells 
To determine the how much VCP associates with A56, we infected cells with a 
previously described recombinant VACV expressing a tagged A56 (131).  BSC-1 cells 
were infected with vA56TAP or a virus expressing an untagged A56 (vv-VCPwt).  48 
hours later, cell lysates were harvested in RIPA buffer and incubated with streptavidin 
sepharose beads for 1 hour at 4° C.  After washing and eluting the protein, western blots 
were performed using a rabbit polyclonal anti-A56 antibody and the mouse monoclonal 
anti-VCP antibody 3D1 (48).   
 
Infection of cells for FACS or immunofluorescence 
For VACV and ECTV infection of cells for cell sorting, RK-13 cells were infected in 
wells of a 6-well plate for 24 hours with ectromelia, vv-VCPwt, and vv-VCPko.  The 
cells were then collected, transferred to FACS tubes, and stained with a rabbit anti-VCP 
Ab and the mouse anti-A56 mAb as described above.  For immunofluorescent images of 
MPXV infected cells, BSC-40 cells in eight-well chamber glass slide (Nunc) at ~50% 
confluency were infected with 1 pfu/cell of either VACV, MPXV-USA, or MPXV-
Congo and incubated for 18 hours in 6% CO2 incubator at 35.5oC.  After a PBS wash, the 
cells were fixed for 30 min with 2% PFA in PBS, followed by washes and blocking with 
5% BSA in PBS for 1 hr. 30 min at room temperature (RT).  Cells were then stained for 2 
hours at RT with anti-VCP mouse monoclonal antibody 2E5 at a 1:40 dilution in 5% 
BSA.  After PBS washes, wells were incubated in the dark for 2 hr. at RT with Alexa 
Fluor 488 goat anti-mouse IgG (Invitrogen) at 1:200 in 5% BSA.  Wells were washed, 
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mounted in VECTASHIELD hard set mounting medium containing DAPI, and images 
were taken at X400 magnification under oil immersion. 
 
Mice for intranasal and intradermal infections 
For all mouse experiments, 6-8 week old female C57BL/6 mice were purchased from the 
Jackson Laboratory and housed in a specific pathogen-free facility at the University of 
Pennsylvania.  For intranasal infections, mice (N=5 per group) were infected with 103, 
104, or 105 pfu of the indicated viruses and weight loss was measured as has been 
previously described (140).  For intradermal infections, groups of mice were anesthetized 
and inoculated in both ear pinnae with 10 µl of the indicated virus diluted to 2x103 pfu/µl 
in PBS (2x104 pfu/ear) using a 29-gauge insulin syringe (BD).  Mice were monitored for 
lesion development and lesions greater than 1 mm in diameter were measured using 
digital calipers.  Experiments were conducted in accordance with the guidelines of the 
University of Pennsylvania Institutional Animal Care and Use Committee.  Statistical 
analysis was performed using Prism.  Unpaired Student’s T tests were used to compare 
differences in weight or lesion size between two groups, and a two-way ANOVA was 
used to compare differences in lesion size between three groups. 
 
 
Results 
VCP cell surface expression is dependent on A56 and does not require other viral 
proteins 
Expression of viral proteins in transfected cells.  VCP, VCPmut and A56 were cloned into the 
pCAGGS expression vector and transfected into 293T cells either alone or in combination.  After 48 
hours, the cells were harvested and stained for flow cytometry under non-permeablized conditions with 
anti-VCP and A56 Abs followed by appropriate secondary Abs.  The histogram represents VCP 
expression on cells that stained A56 positive. 
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Previously, our lab showed that expression of VCP on the infected cell surface is 
mediated by an interaction with the viral A56 protein and requires a free N-terminal 
cysteine on VCP (36).  To investigate if A56 is sufficient for VCP surface expression, we 
transiently transfected cells with plasmids expressing wild type VCP (VCPwt), a mutated 
VCP lacking the free N-terminal cysteine (VCPmut), and wild type A56 (A56wt).  We 
found that when VCPwt is transfected into 293T cells, it is not expressed on the cell 
surface (Fig. 4.1A).  However, when VCPwt and A56wt are co-transected, VCP is 
expressed on the surface of cells that are also A56 positive (Fig. 4.1B).  Importantly, cell 
surface expression is lost when VCPmut is transfected with A56wt (Fig. 4.1C), indicating 
that the transient transfection system reproduces what we saw in cells that were infected 
with viruses expressing either VCPwt or VCPmut (36).  In transfected cells that are A56 
positive, a 2-log10 shift in mean fluorescence intensity (MFI) can be seen between VCPwt 
and VCPmut (Fig. 4.1D). 
  In native western blots, A56 is found as a monomer and a higher molecular 
weight band ((131) and data not shown).  The existence of a strong monomer band 
suggests that a surplus of A56 exists relative to the amount of K2 and VCP on the surface 
of cells.  To begin to assess how much VCP is bound toA56, a recombinant VACV 
expressing a TAP-tagged version of A56 (131) was used to co-precipitate VCP.  We 
found that when tagged A56 was pulled down with Streptavidin beads, VCP co-
precipitated (Fig. 4.1E).  However, only a small amount of VCP is present relative to the 
amount of A56-TAP and to the proteins from the input infected cell lysates.  This 
suggests that a surplus of A56 exists relative to the amount of VCP on the surface of 
cells. 
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Fig. 4.1: VCP and A56 interact on transfected and infected cells.  VCP, VCPmut, and 
A56wt were transfected into 293T cells either alone or in combination.  48 hours later, 
the cells were collected and stained under nonpermeablized conditions for FACS staining 
with an anti-VCP polyclonal antibody and anti-56 mAb LC10.  A) VCP is not expressed 
on the cell surface when transfected alone.  B, C) VCP, but not VCPmut, is expressed on 
the cell surface in the presence of A56.  D) Levels of VCP expression on A56 positive 
cells.  Black solid line represents cells transfected with VCP and A56wt; gray shaded 
area is cells transfected with VCPmut and A56wt.  E) VCP is present after pulling down 
A56-TAP with streptavidin from cells infected with vA56TAP.  Western blots were 
probed with anti-A56 and anti-VCP antibodies to show the presence of the indicated 
proteins.  Boxed areas on the left represent blots of the input cell lysate from vA56TAP 
infected cells.  Boxed areas on the right represent blots of the proteins pulled down with 
streptavidin from cells infected with virus expressing untagged A56 (WT) or from cells 
infected with virus expressing TAP-tagged A56 (A56-TAP). 
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Cysteine 162 of A56 is required for VCP cell surface expression 
The fact that VCP required its N-terminal cysteine to bind A56 suggested to us that either 
a disulfide bonded VCP homodimer (68) interacted with A56 to allow surface expression 
or the free cysteine on monomeric VCP formed a disulfide bridge with an unpaired 
cysteine in the A56 ectodomain.  To investigate which model best explained the 
interaction of VCP with A56, we mutated each of the three cysteine residues in the 
ectodomain of A56.  Each cysteine was mutated to a serine residue and the resulting 
expression plasmids were named A56mut1, A56mut2, and A56mut3, respectively (Fig. 
4.2A).  If an intermolecular bridge was required for surface expression of VCP, the loss 
of VCP’s cysteine partner on A56 would prevent VCP expression on the cell surface.  
While the anti-A56 mAb LC10 used in Figure 1 could detect A56mut3, it no longer 
recognized A56mut1 and A56mut2 (data not shown) indicating that the mAb LC10 
recognizes a conformation epitope that is lost when either Cys34 or Cys103 is mutated.  
However, when we used a rabbit polyclonal Ab raised to a peptide in the A56 ectodomain 
(131), all 3 mutants were recognized and were expressed at the cell surface at levels 
similar to A56wt (Fig. 4.2B).  This indicates that the conformational epitope lost in 
A56mut1 and A56mut2 did not result in drastic misfolding and loss of the trafficking of 
A56muts to the cell surface.  Each of the mutants was examined for their ability to 
interact with VCP and result in surface expression of VCP.  When VCP was co-
transfected with either A56mut1 or A56mut2, the level of VCP cell surface expression 
was similar to cells co-transfected with A56wt (Fig. 4.2C).  A double mutant 
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Fig. 4.2: A56 mutagenesis and VCP surface expression.  A) Schematic of the cysteine 
pattern in the ectodomain of A56 and the three cysteine mutant A56 proteins.  B) 
Expression levels of A56wt vs. A56mut1, A56mut2, A56mut3, and A56mut1+2.  C) 
Cells positive for A56 expression were gated and analyzed for VCP expression.  Mean 
fluorescence Intensity (MFI) levels are listed in the table to the right of the figure.  VCP 
was co-transfected with the indicated A56 construct and stained with anti-VCP mAb 
3F11 and the anti-A56 rabbit Ab and appropriate secondary Abs, and analyzed. 
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(A56mut1+2) is also able to interact with VCP and result in surface expression at levels 
similar to A56wt (data not shown).  These results indicate that Cys34 and Cys103 are not  
required for VCP to interact with A56.  However, when cells are co-transfected with 
A56mut3, VCP is not found on the cell surface, and has an expression profile similar to 
VCPmut + A56wt (Fig. 2C).  This demonstrates that surface expression is lost even when 
the free N-terminal cysteine on VCP is present and homodimers can form.  Taken 
together, these experimental results support a model in which cell surface expression of 
VCP is dependent on formation of a disulfide bridge between VCP and A56. 
 
A56mut3 retains the ability to bind K2 
It is possible that mutating Cys162 of A56 could cause misfolding of the protein, 
resulting in the lack of VCP interaction with A56mut3.  Therefore, we examined the 
ability of A56mut3 to interact with the viral K2 protein, which binds to A56 non-
covalently.  As was previously been shown by the Moyer group (125), transfecting K2 
alone does not result in cell-surface expression of K2 (data not shown).  Also as 
previously reported (125, 132), we found that K2 is expressed on the surface of cells in 
the presence of A56wt (Fig. 4.3).  We also found that in the presence of A56mut3, K2 is 
still expressed on the surface of cells at the same level as with A56wt.  These data 
suggest that mutating cys162 specifically abrogates the A56-VCP interaction without 
affecting the interaction between A56 and K2. 
 
The variola virus VCP ortholog binds the vaccinia A56 protein 
The unpaired N-terminal cysteine in VCP is conserved in many VCP orthologs, including  
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Fig. 4.3:  A56mut3 is able to bind K2.  293T cells were transfected with A56wt alone, 
or with K2 plus A56wt and A56mut3.  The cells were then stained with anti-K2 mAb 
4A11-4A3 and the rabbit anti-A56Ab.  A56 positive cells were gated on and used to 
create a histogram.  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the CCP proteins expressed by variola virus (smallpox inhibitor of complement enzymes 
(SPICE)) and ectromelia virus (ectromelia inhibitor of complement enzymes (EMICE)).  
The monkeypox inhibitor of complement enzymes (MoPICE) has lost this N-terminal 
cysteine, but due to a truncation right after the start of the fourth SCR it has an unpaired 
cysteine near its C-terminus (19, 68).  Additionally, all of these viruses contain a 
homolog to the vaccinia A56 protein, and interestingly, all of these A56 orthologs retain 
the 3 extracellular cysteines (Fig. 4.4).  Therefore, we hypothesized that the interaction 
between A56 and poxvirus CCPs may not be limited to VACV.  To test this, we first 
studied the ability of SPICE to interact with VACV A56.  We found that SPICE bound to 
vaccinia A56 (Fig. 4.5A).  We also found that SPICE, like VCP, is not expressed on the  
cell surface when co-transfected with A56mut3 (Fig. 4.5B).  This suggests that SPICE 
and A56 can interact on the cell surface through a disulfide bridge at Cys162 similar to 
VCP and A56. 
 
EMICE, but not MoPICE, binds to its cognate A56 homolog efficiently 
While VCP and SPICE have identical first SCR domains, EMICE has 12 amino acid 
differences in its first SCR.  Co-transfection of EMICE with vaccinia A56 produced weak 
EMICE surface staining (Fig. 4.5C).  However, staining of cells infected with ECTV 
showed that surface staining of EMICE was clearly evident (Fig. 4.5D) and that EMICE 
expression was similar to VCP expression on vaccinia infected cells (Fig. 4.5D).  This 
suggested to us that EMICE can interact with its A56 cognate, but not vaccinia A56.  To 
address this possibility, we cloned the ECTV homolog of A56 (ECTV-A56) and co-  
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Fig. 4.4: Comparison of Orthopoxvirus A56 genes.  The protein sequences of vaccinia 
(VACV-WR) A56 and the homologs in variola (VARV-Bangladesh), monkeypox 
(MPXV-Zaire), and ectromelia (ECTV-Moscow) were downloaded from poxvirus.org 
and aligned using BLAST.  Shaded residues indicate identical amino acids to vaccinia 
and dashes represent missing amino acids.  Conserved cysteines in the ectodomain are 
indicated in bold and with an arrow.  The putative transmembrane domain is marked with 
a black line above the residues. 
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transfected it with EMICE.  We found that while VACV-A56 and ECTV-A56 
were expressed on approximately the same number of cells (19.2% vs. 19.8%), EMICE is 
expressed to a much higher level at the cell surface when co-transfected with ECTV-A56 
(Fig. 4.5E).  The peak level of EMICE staining on cells transfected with ECTV-A56 was 
2-logs higher than EMICE transfected in cells with VACV-A56 or VACV-A56mut3 (Fig. 
4.5F).  This shift in staining mirrors the expression levels of VCP when it is transfected 
with vaccinia A56. 
 The monkeypox homolog of VCP, MoPICE, differs from these other poxvirus 
CCPs in several respects.  As has been reported elsewhere, MoPICE does not have a free 
N-terminal cysteine, as this initial residue is a tyrosine (68).  Also, MoPICE only contains 
3 SCRs due to a point mutation that results in a truncation after the start of the fourth 
SCR.  Interestingly, this truncation results in an unpaired cysteine near the C-terminus 
through which MoPICE can form homodimers (20).  Immunofluorescence of cells 
infected with MPXV-Congo shows weak cell surface staining of MoPICE when 
compared to vaccinia-infected cells (Fig. 4.6A).  Consistent with the lower level of 
surface expression compared to VCP expression on vaccinia infected cells, co-
transfection of MPXV A56 with MoPICE also results in low level surface expression of 
MoPICE (Fig. 4.6B, C), with only 2.48% of cells double positive.  These data suggest 
that MoPICE is not expressed at high levels on infected or transfected cells.  Taken with 
the EMICE data, it appears that the first SCR domain with an N-terminal free cysteine is 
crucial for optimal binding to A56. 
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Fig. 4.5: SPICE and EMICE are also expressed on the cell surface in the presence of 
A56.  SPICE is expressed on cells co-transfected with vaccinia A56wt.  A) Scatter plot of 
SPICE co-transfected with A56wt.  B) Histogram of SPICE expression on A56 positive 
cells.  The black line is SPICE transfected with vaccinia A56wt, and the shaded grey area 
is SPICE transfected with A56mut3.  C) Scatter plot of EMICE transfected with VACV 
A56.  D) Histogram of CCP expression on virus infected cells.  RK-13 cells were 
infected with ECTV, VACV, or vv-VCPko and then stained with a polyclonal anti-VCP 
antibody.  Shown is a histogram of surface staining due to EMICE  (black line), VACV 
(dotted line) or vv-VCPko (grey shaded area).  E) Scatter plot of EMICE co-transfected 
with ECTV A56.  F) Histogram of EMICE expression of cells co-transfected with ECTV 
A56 (black line), VACV A56 (dotted line), and VACV A56mut3 (grey shaded area). 
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Vaccinia expressing VCPmut is attenuated in vivo 
The N-terminal cysteine residue in VCP is conserved among other PICEs and has been 
shown to mediate both cell surface expression and dimerization of VCP (36, 68).  Both 
cell surface expression and dimerization of recombinant VCP have been shown to 
enhance its complement regulatory function in vitro (68).  In order to determine if cell 
surface expression and/or dimerization contribute to VCP’s function as a virulence factor, 
we assessed the virulence of our recombinant VACVs using two mouse models of VACV 
pathogenesis (Fig. 4.7).  We first compared vv-VCPmut to vv-VCPko and vv-VCPrescue 
after intranasal inoculation.  At the lowest dose (103 pfu), all of the mice survived, but 
mice infected with vv-VCPrescue lost slightly more weight (Fig. 4.7A).  The difference 
in weight loss between vv-VCPrescue and the other two viruses was significant at days 7 
and 8.  At the intermediate dose (104 pfu), all of the mice infected with the VCP rescue 
virus died, while mice infected with the VCPko and VCPmut mice lost approximately the 
same amount of weight (Fig. 4.7B).  At a high dose (105 pfu), all of the animals lost 
weight at a similar rate and died (data not shown).   These experiments show that after 
intranasal inoculation a virus expressing wild type VCP is more pathogenic than viruses 
with VCP deleted or ones lacking the N-terminal cysteine on VCP (and thus unable to 
form homodimers and/or be expressed on the cell surface).  Interestingly, by this route of 
infection, vv-VCPko and vv-VCPmut have similar virulence.  We also examined 
pathogenesis of vv-VCPko and vv-VCPmut using an intradermal model of infection (122, 
123).  We initially showed that vv-VCPko made smaller ear lesions than vv-VCPwt (and 
vv-VCPrescue; Fig. 4.7C).  We then infected mice intradermally with a recombinant 
VACV encoding VCP lacking the free N-terminal cysteine (vv-VCPmut) and compared  
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Fig. 4.6: MoPICE is expressed on the cell surface at low levels. A) 
Immunofluorescence of infected cells.  BSC-40 cells were infected for 18 hrs with 
MPXV-Congo, VACV, or CCP-minus strain of MPXV, MPXV-USA, and fixed and 
stained using anti-VCP mAb 2E5 and fluorescent secondary Ab.  To better visualize the 
cell distribution of VCP or MoPICE, the white box indicates the area of the image that 
was enlarged, but unaltered.  B) Scatter plot of MoPICE co-transfected with MPXV A56.  
C) Histogram of MoPICE expression on A56-positive cells.  MoPICE was co-transfected 
with MPXV-A56 (black line) or VACV A56mut3 (grey shaded area) and cells were then 
stained for FACS with polyclonal rabbit anti-VCP and anti-A56 mAb. 
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lesion sizes formed by this virus to those formed by a virus encoding wild type VCP (vv-
VCPwt) or a virus that lacks VCP (vv-VCPko) (Fig. 4.7D).  The lesions formed 
following infection with vv-VCPmut were larger than those formed by vv-VCPko, but 
smaller than those formed by vv-VCPwt.  These differences in lesion sizes were 
statistically significant.  The finding that vv-VCPko is attenuated following intradermal 
infection in mice confirms that VCP contributes to pathogenesis and is similar to what 
was reported in the past in rabbits and guinea pigs (50).  Furthermore, as opposed to the 
intranasal route of inoculation where VCPko and VCPmut were similarly attenuated, by 
the intradermal route vv-VCPmut formed lesions of intermediate size between vv-VCPko 
and vv-VCPwt.  This suggests that the ability of VCP to bind to the cell surface and/or 
dimerize contributes to pathogenesis. 
 
Discussion 
VCP has been previously characterized as the major protein secreted from VACV 
infected cells (57, 59) and has only recently found to also be expressed on the infected 
cell surface (36, 57, 59).  The N-terminal cysteine of VCP is necessary for surface 
expression; however, the precise mechanism by which VCP interacted with A56 was 
unknown.  We have found that the primary method for VCP surface expression is 
through a disulfide bridge with Cys162 of the viral A56 protein.  Mutation of A56 Cys34 
and/or Cys103 results in loss of recognition by an anti-A56 monoclonal antibody LC10.  
However, despite the loss of recognition by this antibody, these mutated proteins can still 
traffic to the cell surface and interact with VCP.  Our work therefore also provides 
important information about A56.  While cysteines 34 and 103 of A56 are unnecessary  
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Fig. 4.7: Wild type VCP is needed for full virulence in mice.   Our panel of 
recombinant viruses was studied in 6-8 week old female C57BL/6 mice either after 
intranasal (A & B) or intradermal (C & D) inoculation.  In A & B, shown is the average 
weight loss of 6-week old mice infected with vaccinia encoding VCPrescue, VCPmut, or 
VCPko at 103 pfu (A) or 104 pfu (B).  N=5 for all groups.  # sign indicates that all mice 
infected with vv-VCPrescue died; ✝ sign indicates a single mouse in the group infected 
with vv-VCPko died.  * indicates p<0.05 on the days indicated between VCPrescue and 
VCPko and between VCPrescue and VCPmut (unpaired Student’s T test).  In C & D, 
shown are lesion diameters in 6-8 week old mice inoculated with 2x104 pfu of C) 
VCPrescue, VCPwt, and VCPko and D) VCPwt, VCPko and VCPmut.  For C, data 
points represent the mean lesion diameter ± SEM of 10 infected ears per group (two ears 
per mouse).  P values for the difference between VCPko and VCPwt and between VCPko 
and VCPrescue for each day are as indicated:  * for p<0.05, ** for p<0.01, and @ for 
p<0.001 (unpaired Student’s T test).  For D, data points represent the mean lesion 
diameter ± SEM of 20 (VCPko), 14 (VCPwt), or 10 (VCPmut) infected ears per group 
(two ears per mouse).  Differences in lesion size between the groups of mice were 
statistically significant (two-way ANOVA; p < 0.01).  
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to bind VCP, they may play a role in the folding of A56.  The N-terminal domain of A56 
has homology to the Ig superfamily, which is heavily disulfide bonded.  It is possible that 
the first two cysteines in A56 form an intramolecular bridge that when mutated, alters an 
epitope recognized by mAb LC10.  But the mutated protein still maintains sufficient 
folding to allow the protein to properly traffic to the cell surface. 
VCP forms a disulfide bond with Cys162 of A56 and we have shown that this 
specific interaction also occurs with other poxviruses proteins, like SPICE.  Soluble 
SPICE is capable of the same catalytic activity as VCP, but with a 100-1000 fold increase 
in activity against human complement (69, 98, 107).  Therefore, it is interesting to 
speculate that expression of SPICE on the infected cell surface may have contributed to 
its significant pathogenesis in humans.  Another significant finding is the interaction 
between the ectromelia homolog of VCP and A56.  EMICE, in contrast to SPICE, is only 
able to interact efficiently with its own homolog of A56.  This raises the intriguing 
possibility that co-evolution has occurred in these two proteins, as EMICE and ectromelia 
A56 are less similar to the vaccinia proteins than their variola counterparts.  Conversely, 
the lack of high surface expression of MoPICE may mean that efficient cell surface 
expression of MoPICE is not possible without an N-terminal cysteine, even in the 
presence a C-terminal free cysteine.  This is interesting because it has been shown that 
this free C-terminal cysteine can form homodimers in a similar fashion as the orthologs 
with a free N-terminal cysteine (68). 
We have also shown that a virus that cannot express cell surface VCP is modestly 
attenuated in vivo.  This finding, combined with earlier in vitro data showing that 
compared to cells infected with a VCP-deletion virus, wild type vaccinia infected cells 
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are resistant to complement mediated lysis (36), suggests that the ability of VCP to 
interact with A56 and be expressed on the cell surface may have important implications 
for poxvirus pathogenesis.  After ear pinnae infection, VCPmut formed larger lesions 
than VCPko.  This is not entirely unexpected since the majority of VCP is a secreted 
monomer.  Therefore, when VCP is mutated so that it cannot form homodimers and/or be 
expressed on the cell surface, VCP still has complement regulatory activity.  However, 
since mutating the N-terminal cysteine also abrogates dimerization of VCP, the 
contribution of secreted VCP homodimers to the attenuated lesion size we observed is not 
known.  Our biochemical analysis of the interaction between VCP and A56 has identified 
a mutation in A56 that disrupts the A56-VCP interaction without disrupting the A56-K2 
complex.  Comparing pathogenesis of vv-VCPmut with a recombinant virus expressing 
A56mut3 will allow us to define the roles of surface bound VCP and dimeric VCP in 
poxvirus pathogenesis.  As opposed to the intradermal route of infection where we found 
statistically significant differences between lesions formed by VCPko and VCPmut, these 
viruses appeared to be similarly attenuated after intranasal inoculation of mice.  This may 
indicate that in a lung pneumonia model, the contribution of cell surface expression 
and/or the formation of the VCP homodimer is important for VCP’s contribution to 
pathogenesis.  Again, work with a recombinant virus expressing A56mut3 will allow us 
to define the roles of surface bound VCP and dimeric VCP in poxvirus pathogenesis. 
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Abstract 
The vaccinia virus complement control protein (VCP) is both secreted from and 
expressed on the surface of infected cells.  Surface expression of VCP is due to an 
intermolecular di-sulfide bond formation with the viral transmembrane glycoprotein 
called A56.  The covalent interaction of these two proteins require a free N-terminal 
cysteine on VCP and an unpaired cysteine in the ectodomain of A56 at amino acid 162.  
Here, we generated and characterized a novel recombinant vaccinia virus that contains a 
cysteine to serine mutation at residue 162 in A56 (vvA56mut3).  We show that the 
mutated A56 surface expression is unaffected on cells infected with vvA56mut3, as well 
as the ability of A56 interact with K2 and inhibit syncytia formation.  However, VCP is 
no longer expressed on the cell surface.  In vivo, when vvA56mut3 is compared to its 
parental virus (vvA56ko) and the rescue virus (vvA56rescue), vvA56mut3 is attenuated 
and this attenuation is dependent upon the presence of the host complement system.  
These results indicate that the ability of A56 to bind VCP and express it on the surface of 
infected cell is important for full vaccinia virus virulence.  
 
Introduction 
Poxviruses are some of the largest and most complex of all viruses.  Vaccinia virus 
(VACV), the most studied and prototypical poxvirus, has a ~190 kb long genome (38).  
Besides genes necessary for viral replication, poxvirus genomes contain a large number 
of non-essential genes.  Many of these are needed to replicate in certain cell types (i.e., 
host range genes) or increase pathogenesis in vivo (i.e., virulence genes) (27, 73, 95).  
One non-essential VACV gene is in the open reading frame (ORF) A56R, which encodes 
a protein initially called the VACV hemagglutinin (46, 87).  This protein is now more 
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commonly called A56.  A56 is a glycosylated transmembrane protein that is expressed on 
the surface of infected cells as well as on an infectious form of VACV called the 
extracellular virus (EV) (11, 94, 109).  Although it was initially characterized as a viral 
hemagglutinin due to its ability to bind chicken erythrocytes, the important functions of 
A56 during viral infection are unrelated to its hemagglutinating activity.  A56 binds two 
viral proteins and allows them to be expressed at the infected cell surface.  A56 interacts 
noncovalently with K2 (125).  This A56/K2 complex interacts with the VACV 
entry/fusion complex to prevent syncytia formation and superinfection of infected cells 
(128, 131-133).  K2, which is also called serine protease inhibitor (SPI)-3, is a soluble 
protein that is dependent on A56 for surface expression.  While the serine protease 
inhibitor activity is not required for prevention of infected cell synctia formation (125), 
both A56 and K2 must be present at the infected cell surface to prevent syncytia 
formation (47, 62, 127, 147) and superinfection (128, 132). 
A56 also forms a heterodimer with the vaccinia complement control protein 
(VCP) (36).  While A56 interacts non-convalently with K2, the A56-VCP interaction 
results in a covalent bond between unpaired cysteines present in both proteins (23).  VCP 
is related to the superfamily of host regulators of complement activation and is able to 
disrupt the complement cascade at multiple steps (9, 68, 69, 76, 86, 97, 98, 100), and has 
been shown to be a virulence factor during in vivo infections (23, 50).  VCP was initially 
characterized as the major protein secreted from infected cells (59), and most of its 
complement regulatory activity has been examined as a purified soluble protein.  
However, surface bound VCP can protect infected cells from complement attack (36), 
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and recent evidence suggests that surface expression is necessary for full virulence in 
vivo (23, 36). 
Studies of A56’s contribution to VACV virulence have been inconsistent.  In 
some models, A56 knockout viruses are attenuated relative to wild-type viruses.  Studies 
that showed attenuation in mice were with the NYCBH strain and WR strain given 
intracranially (31, 64).  This attenuation with NYCBH strain was also seen after 
intranasal challenge (64).  However, little or no attenuation in mice was seen using 
VACV strains LC16mO or LO given either by an intracranial or intraperitoneal route 
(112).  In retrospect, this is not surprising given that we now know A56 has multiple 
functions, which may have varying importance to virulence depending on virus strain and 
the model of infection used.  Here, for the first time, we attempt to separate the functions 
of A56.  We show that a recombinant VACV containing an A56 protein that can bind K2 
but not VCP is attenuated in vivo, using both mouse intranasal and intradermal models of 
infection.  Importantly, using mice with the central complement component C3 
genetically deleted, we also show that the attenuation of the mutant virus that does not 
express VCP on the surface of infected cells is complement-dependent. 
 
Methods 
Cells and Viruses 
Viruses were grown and titered in BSC-1 cells (ATCC® Number CCL-26TM) in MEM 
supplemented with 2.5% FBS and antibiotics/antimycotics at 37oC in a 5% CO2 
atmosphere.  Plasmids were first constructed to allow the generation of recombinant 
vvA56mut3 and vvA56rescue.  The plasmid containing the A56mut3 gene was created 
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using Splicing by Overlap Extension (SOE) PCR with primers that mutate the third 
cysteine of A56 (ol-205 and ol-206 (23)), paired with ones that anneal to the left and right 
flanking DNA adjacent to the A56R ORF (ol-156 and ol-159 (36))  These latter primers 
were then used to generate a single PCR product that contained the mutated A56R ORF 
along with flanking sequences.  This PCR product was cloned into the TOPO 2.1 plasmid 
to generate pAS279 (pA56mut3).  A56rescue was created by first digesting out bases 42-
505 of the A56 ORF from pAS279 using the restriction enzymes NruI and BstZ17I and 
isolating a 463 bp fragment of A56 (bases 42-505 of the ORF). This DNA was used 
along with primers that annealed to the left and right flanking DNA adjacent to the A56R 
ORF (ol-156 and ol-159) and WR DNA as a template to generate two fragments.  Primers 
ol-156 and ol-159 were then used to generate a single PCR product that contained the 
wild type A56R ORF along with flanking sequences.  This product was cloned into the 
TOPO 2.1 plasmid to generate pBD281 (pA56rescue).  The plasmids were sequenced to 
confirm that no unwanted mutations were accidentally generated during the PCR 
reactions and cloning.  The plasmids then transfected into individual flasks containing 
CV-1 cells (ATCC CCL-70™) that had been infected with a previously described 
recombinant VACV lacking the A56R ORF (vvA56ko, (36)).  vvA56ko had the entire 
A56R ORF replaced with a beta-glucuronidase (GUS) screening cassette (16).  Fourty-
eight hours after infection and transfection, the cells were harvested, lysed with freeze-
thawing and sonication, and used to infect RK-13 cells (ATCC® Number CCL-37TM) for 
a second round of growth.  The lysate from this growth was then used to infect RK-13 
cells and 24 hours after infection, infected cells underwent live-cell sorting to isolate cells 
infected with the recombinant viruses.  Cells containing the A56 rescue virus 
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(vvA56rescue; virus # vBD219e4-1) were isolated by collecting cells with surface 
expression of VCP using an anti-VCP monoclonal antibody 3F11 (48).  Cells containing 
the mutated A56  (vvA56mut3; virus #vBD217f2-1) were collected based on cell-surface 
A56 expression using the anti-A56 mAb LC10 (78).  Collected cells were lysed and the 
released virus underwent three rounds of plaque purification in the presence of X-Gluc 
(16).  During plaque purifications, any remaining parental virus (vvA56ko) plaques 
stained blue.  By the third plaque purification, all plaques were white in the presence of 
X-Gluc indicating that the GUS cassette had been successfully replaced with A56wt or 
A56mut.  Isolated viruses were confirmed by PCR.  Virus from plaques were grown and 
amplified in BSC cells and virus used for animal challenge were pelleted through two 
sequential 36% sucrose cushions. 
 
Antibodies and flow cytometry 
Infected cells were studied by flow cytometry using methods similar to what were 
previously described (23).  Briefly, RK-13 cells were infected in 6-well plates at an MOI 
of ~1 pfu/cell with the indicated virus.  After 24 hours, cells were harvested in FACS 
buffer (PBS with 1% BSA and 0.04% sodium azide) and stained with primary antibodies 
at dilutions of 1:1000.  Primary antibodies included an anti-K2 mouse mAb 4A11-4A3 
(15), an anti-A56 rabbit polyclonal antibody raised to an A56 peptide (131), an anti-VCP 
mouse mAb 3F11 (48), and a polyclonal anti-B5 rabbit antibody (UP2197).  After 
washing in FACS buffer for 45 minutes, an anti-mouse APC-conjugated secondary Ab 
and an anti-rabbit FITC-conjugated secondary Ab were added at dilutions of 1:40.  After 
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30 minutes, the cells were washed, fixed in 3% paraformaldehyde, and loaded into a 
FACScaliber machine.  Data analysis was performed via FlowJo. 
 
Western blots 
BSC-1 cells in a 6-well plate were infected with the indicated virus at an MOI of 5.  After 
24 hours, the cells were harvested and prepared in 100 µl of RIPA buffer (150 mM NaCl, 
0.1% SDS, 50 mM Tris). 4× reducing/denaturing sample buffer was added to a 20 µl 
volume of each sample, and loaded onto a 10% Tris-Glycine gel.  After transferring to 
nitrocellulose, the blot was blocked PBS/0.01% Tween with 10% milk fat, and then 
incubated overnight at 4 oC with shaking with an anti-A56 rabbit antibody (131) at a 
1:5000 dilution.  After washing in PBS-0.01% Tween, an anti-rabbit HRP-conjugated 
secondary Ab at 1:5000 was added for one hour. Chemiluminescence was used to 
visualize bands. 
 
Animal infections 
C57BL/6 mice were purchased from the Jackson Laboratory.  Complement component 
C3 knockout mice (C3-/-) on the C57BL/6 background (originally provided by J. D. 
Lambris, University of Pennsylvania) were bred at the University of Pennsylvania.  Mice 
were housed in a specific-pathogen-free facility at the University of Pennsylvania.  For 
intranasal infections, mice were anesthesized and infected with ~104 PFU of the indicated 
viruses in 20 µl volume (10 µl/nostril), and weight loss was measured as has been 
previously described (23).  For intradermal infections, groups of mice were anesthetized 
and inoculated in both ear pinnae with ~2x104 pfu of the indicated virus using a 29-gauge 
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insulin syringe (BD).  Mice were monitored for lesion development, and when lesions 
reached a 1 mm in diameter threshold, they were measured using digital calipers.  
Experiments were conducted with the approval of the University of Pennsylvania 
Institutional Animal Care and Use Committee. 
 
Results 
Characterization of recombinant viruses 
Previously, our lab has shown that the N-terminal cysteine (residue 20) on VCP (36) and 
the third extracellular cysteine of A56 (residue 162) (23) were necessary for surface 
expression of VCP.  The prior data showing the importance of A56 cysteine-162 for VCP 
surface expression was based on the transfection of plasmids expressing the proteins in 
uninfected cells.  To investigate whether this finding was also true during viral infection, 
we constructed a recombinant VACV that contained a cysteine to serine mutation at 
residue 162 (vvA56mut3).  This virus was generated from an A56-knockout virus.  As a 
control, we also made a rescue virus producing wild-type A56 (vvA56rescue).  
A56rescue contains the VCP-binding cysteine residue at position 162, while in A56mut3 
this cysteine has been mutated to a serine (Fig. 5.1).  As shown in western blots, these 
two new viruses, but not the parental A56ko virus, produce the A56 protein (Fig. 5.2A).  
Using flow cytometry of infected non-permeablized cells, both A56rescue and A56mut3 
are able to bind K2 and express it on the cell surface at levels comparable to cells 
infected with a stock of wild type WR virus (Fig. 5.2B). 
In contrast to the ability of A56 to bind K2, mutating the third cysteine of A56 
abrogates its ability to bind VCP.  VCP expression on infected cells is markedly lower  
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Fig. 5.1: Schematic of A56 proteins.  The ectodomain of A56 contains an unpaired 
cysteine at residue 162.  This cysteine can form a disulfide bridge with VCP (23).  In the 
virus vvA56mut3, this cysteine has been mutated to a serine, abrogating surface 
expression of VCP.  A56 and A56mut3 can also bind K2; we use a K2ko virus to remove 
the A56/K2 complex. 
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than the rescue virus (Fig. 5.2C).  In fact, vvA56mut3 has approximately the same level 
of surface VCP as vvVCPmut (36) (Fig. 5.2D).  In VCPmut, the N-terminal cysteine has 
been mutated to a threonine residue, so it cannot form dimers with either itself or A56.  
Interestingly, both vvA56mut3 and vvVCPmut have slightly higher levels of surface VCP 
expression than vvVCPko (Fig. 5.2D).  Thus, in addition to the high level of surface 
expression due to interactions with A56, some VCP can also bind the RK cell surface via 
non-covalent interactions as suggested by others (68, 116). 
 
A56mut3, but not A56ko, is attenuated in an intranasal mouse challenge model 
We first examined virulence by infecting groups of mice intranasally with each 
virus.  At a challenge dose of ~104 pfu per mouse, we found that vvA56rescue is as 
virulent as the previously characterized wild-type virus vvVCPrescue (23).  We also 
found that in this challenge model, vvA56ko is not attenuated, as mice infected with this 
virus lose the same amount of weight as the two rescue viruses (Fig. 5.3).  Somewhat 
surprisingly, given this finding with the A56ko virus, vvA56mut3 is attenuated in this 
model.  We also saw a similar amount of attenuation with vvVCPmut in this system (data 
not shown).  Mice infected with this virus lose less weight and this difference is 
statistically significant at the peak of infection.  This suggests that an intranasal model 1), 
losing the VCP/A56 complex attenuates the virus, and 2) the loss of the A56/K2 complex 
may actually restore this virulence.   
 
A56mut3 and A56ko are attenuated in an intradermal mouse challenge model 
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Fig. 5.2:  Characterization of recombinant viruses.  A) vvA56mut3 and vvA56rescue 
produce the A56 protein while vvA56ko does not.  Western blotting was performed on 
infected BSC cell lysate using an anti-A56 antibody.  A stock of WR virus was used as a 
positive control.  B) Recombinant A56 viruses still express K2 on the cell surface.  
Infected RK-13 cells were stained with anti-K2 and -A56 antibodies under non-
permeablized conditions.  Infected (A56 positive) cells were gated on and analyzed for 
levels of K2 expression. 
  80 
 
Fig. 5.2, continued:  C, D) A56mut3 does not express VCP on the cell surface.  Infected 
RK-13 cells not otherwise gated were stained with an anti-VCP antibody under non-
permeablized conditions.  Panel C compares the recombinant A56 viruses to a stock of 
WR virus; panel D compares vvA56mut3 to the previously characterized recombinant 
VCP viruses vvVCPmut and vvVCPko (36), as well as to a stock of WR virus. 
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In addition to the intranasal model, we also infected mice intradermally using an ear 
pinnae model of infection (122).  This system has the advantages of mimicking VACV 
vaccination, and also is able to differentiate small changes in virulence (122).  C57BL/6 
mice were first infected with vvVCPrescue (23) and vvA56rescue to establish the size of 
wild type lesion sizes.  We found that our A56rescue virus produced the same size lesions 
as vvVCPrescue, which has previously been shown to be virulent in this model compared 
to a related panel of mutant viruses (23, 37).  Next, we infected groups of mice with 
vvA56rescue, vvA56ko, or vvA56mut3.  In this model of infection, vvA56ko produces 
smaller lesions than vvA56rescue.  These differences are statistically significant at the 
peak of infection.  vvA56mut3 produced lesions that were of similar size to vvA56ko; at 
day 8 the difference between vvA56mut3 and vvA56rescue is statistically significant.  
However, at days 9 and 10 these differences fall just short of statistical significance (p= 
0.1 compared to A56rescue) (Fig. 5.4B).  The differences in lesion sizes between 
A56resue and A56mut3 were seen in repeated experiments.  Additionally, lesion sizes 
between vvA56mut3 and vvVCPmut were of equivalent size (data not shown).  This may 
mean that while the A56/VCP complex is important for virulence in this model, the 
A56/K2 complex also contributes to maximum pathogenesis.     
 
A56mut3 and A56rescue generate equivalent sized lesions in C3-/- mice 
VCP acts by inhibiting the complement cascade and has previously been shown to be 
important for virulence (50).  Critically, in the intradermal model of infection, differences 
in virulence between a VCPrescue and VCPko virus were not seen in complement 
deficient (C3-/-) mice (37).  If the differences in lesion sizes between vvA56rescue and  
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Fig. 5.3:  Weight loss after intranasal challenge.  6-week-old female C57BL/6 mice 
(N=5 per group) were challenged intranasally with 2x104 pfu of virus.  Average weight 
loss was measured as a percentage of the mice’s starting weight. * represents p<0.05 
between vvA56mut3 and vvA56rescue using an unpaired T-test.  Error bars represent 
SEM. 
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vvA56mut3 are in fact due to the complement-regulatory properties of surface-bound 
VCP, then these two viruses should form equivalent lesions in C3-/- mice.  We therefore 
infected aged-matched groups of C3-/- mice with either vvA56mut3 or vvA56rescue 
intradermally and measured their lesions.  We found that these two viruses do in fact 
form equivalently sized lesions on all days measured (Fig. 5.4C).  The same results were 
seen in groups of male mice (data not shown).  These findings in C3-/- mice indicates 
that the consistently smaller lesions formed by vvA56mut3 in C57BL/6 mice is likely 
dependent on a lack of surface expression of VCP and the presence of host complement. 
 
Discussion 
Currently the VACV A56 protein has three known activities.  It was first described and 
identified a hemagglutinin protein in vitro.  However, at this point, no relevant in vivo 
function has been correlated with this activity.  More recently, two new properties have 
been ascribed to A56.  It binds K2 and VCP and allows these two proteins to be 
expressed at the infected cell surface.  Testing the contribution of A56 to VACV 
virulence has been inconclusive, possibly because of these dual (and/or other) functions.  
Prior in vivo work has focused on gene knockout viruses; however, the two known 
functions of A56 may have differing levels of importance, or even opposite effects in 
vivo. 
Here, for the first time, we provide in vivo data using a recombinant virus with a 
site-directed mutation in A56.  We show that vvA56mut3 is attenuated relative to wild- 
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Fig. 5.4:  Intradermal infection in C57BL/6 and C3-/- mice.  A,B ) 6-week old female 
C57BL/6 mice (n=5) were challenged intradermally with 1x104 pfu of virus in each ear.  
Lesions greater than 1 mm were measured and averaged each day until peak lesion size.  
A) Comparison of rescue viruses.  B) Comparison of vvA56ko, vvA56mut3, and 
vvA56rescue.  C) Comparison of vvA56mut3 and vvA56rescue in 6-8 week old female 
C3(-/-) mice. * represents p<0.05 between vvA56ko and vvA56rescue using an unpaired 
T-test; @ represents p<0.05 for both vvA56ko and vvA56mut3 vs. vvA56rescue.  Error 
bars represent SEM. 
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type A56 in two different models of VACV pathogenesis.  From this work, it appears that 
the A56/VCP interaction is responsible for most of A56’s contributions to VACV 
virulence.  In an intradermal model, both A56ko and A56mut3 have similar levels of 
reduced virulence compared with vvA56rescue.  Importantly, vvA56mut3 and A56rescue 
do not have these differences in C3-/- mice.  This implies that the differences in C57BL/6 
mice are complement dependent, and most likely related to A56mut3’s inability to bind 
VCP.  Previous in vivo work focused on mutating the N-terminal cysteine of VCP to 
abrogate cell-surface expression (23).  However, this cysteine also mediates the 
formation of a VCP homodimer.  It is not known whether this dimer contributes to 
pathogenesis, but in purified form the dimer does possess a higher level of complement 
regulatory activity than the monomer (68).  The recombinant vvVCPmut virus (which has 
the N-terminal cysteine mutated and thus does not form homodimers and is not expressed 
on the cell surface) and vvA56mut3 come from different lineages of parental viruses, so 
direct comparisons may not be valid.  However, vvVCPmut seems to be slightly more 
attenuated than vvA56mut3 compared with their rescue viruses.  This may mean that the 
additional loss of VCP dimers seen in vvVCPmut also has an effect on virulence.  
Regardless, our data with A56mut3 now allows us to conclude that the VCP/A56 
disulfide bridge is important virulence in VACV.  However viruses from the same 
parental line will need to be constructed to make definitive conclusions. 
It is interesting to note that vvA56mut3 is attenuated in the intranasal model of 
infection, while vvA56ko is not.  This may mean that the lack of the A56/K2 complex 
actually may increase virulence in this model of infection.  Perhaps in a lung pneumonia 
model, the potential ability of the virus-infected cells to form syncytia enhances 
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pathogenesis.  However, more research is needed in this area.  It is also possible that in 
other models of infection that the A56/K2 complex has a larger contribution to virulence 
in VACV.  Ideally, a companion mutant A56 virus would be created that cannot bind K2; 
however, little is known about the interaction between these two proteins.  Currently, it is 
only known that the Ig domain in A56 is needed to bind K2 (105).  The first two 
cysteines in A56 have been hypothesized to form a disulfide bridge.  One A56 mutant has 
been described that has hemagluttinating activity but also form syncytia; in this A56 
protein, the 2nd cysteine in the A56 ectodomain is mutated.  This mirrors findings from 
our lab, where tranfected proteins A56mut1 (C34S) or A56mut2 (C103S) appear to have 
reduced ability to bind K2 (unpublished).  Unfortunately, our attempts to isolate 
recombinant viruses producing these proteins were unsuccessful. In conclusion, the 
generation of a recombinant viaccinia virus with a cysteine-to-serine change at residue 
162 in A56, which can no longer result in surface expression of A56, we have shown that 
the A56/VCP complex is important for vaccinia virulence.   
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Chapter 6- Concluding remarks 
 
VACV replication is complex, as it involves both producing new infectious particles as 
well as a myriad of proteins dedicated to combating the host’s immune response.  
Although these proteins are often called “non-essential”, they are frequently needed for 
the virus to establish an infection and spread to other hosts.  This thesis focuses on two 
non-essential proteins: VCP and A56.  VCP, the vaccinia complement control protein, 
which had previously been characterized as the major secreted protein from VACV 
infected cells, has already been established as a viral virulence factor (50).  In chapter 
three, we established that VCP interacts with A56 and that this complex is necessary for 
VCP cell-surface expression.  We also showed that the N-terminal cysteine of VCP is a 
critical residue for this interaction.  In chapter four, we located the residue on A56 that 
allows it to bind VCP.  We also proved that the interaction between these two proteins 
occurs through a disulfide bridge.  Finally, we began to establish that viruses that cannot 
form the A56/VCP complex are attenuated in vivo, using a virus that produces mutated 
VCP.  In chapter five, this in vivo work was extended using recombinant A56-producing 
viruses in intradermal and intranasal mouse challenge models.  A virus producing an A56 
protein that cannot bind VCP was attenuated in both of these infection models.  In this 
section, I will review the major conclusions from chapters three, four, and five; I will also 
discuss possible future directions.   
 
Forming the A56/VCP complex 
The observation that VCP was expressed at high levels on the surface of infected cells 
was initially puzzling.  VCP has been well characterized as a secreted protein and while 
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others had shown that purified recombinant expressed protein could bind to the cell 
surface through interactions with heparan sulfate, we found surface expression could still 
occur in heparan sulfate deficient cell lines (36).  We also discovered that a virus with the 
A56 gene deleted (A56ko) could not express VCP at the cell surface (36).  This was 
noteworthy, as A56 is expressed on the surface of cells and could serve as a binding 
partner for VCP.  Work in chapter three focused on proving that these proteins interacted, 
and began to elucidate the mechanism of this interaction.  Using non-reducing, non-
denaturing western blots, we found that in addition to formation of a VCP monomer and 
dimer, a high molecular weight complex forms in wild-type VACV infection.  This 
complex is lost in cells infected with a A56ko virus, and also when the unpaired N-
terminal cysteine of VCP is mutated to a threonine residue (VCPmut).  In order to show 
that these two proteins physically interact, we incubated cell lysates from cells infected 
with 6x-histidine tagged VCP-producing viruses with nickel agarose.  We found that A56 
co-purified with his-tagged wild-type VCP, but not with his-tagged VCPmut.  This 
provided evidence for an A56/VCP complex, and pointed to the N-terminal cysteine of 
VCP as critical in forming this complex.  However, it was not possible to determine the 
exact nature of the interaction between these two proteins based on this data.  The 
importance of the N-terminal cysteine could mean that a disulfide linkage occurs between 
A56 and VCP.  However, VCP also forms a homodimer via this cysteine (68) and thus 
the importance of the N-terminal cysteine in formation of the A56/VCP complex could 
be the result of a non-covalent interaction between the VCP dimer and A56.  While not 
conclusive, additional work we did with viruses that produced truncated VCP proteins 
supported the first hypothesis.  We found that only the first SCR domain, a portion that 
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represents only ~25% of the full-length protein, was expressed on the cell surface as long 
as a free cysteine was present.  This first SCR domain could be expressed on the cell 
surface even if the unpaired cysteine was located at the C-terminus of the protein.  Since 
the homodimer of such a protein would form a “tail-to-tail” configuration, this suggested 
to us that a free cysteine residue, rather than formation of a VCP homodimer is what 
drives the stable interaction of VCP with A56. 
In chapter four, we show that VCP and A56 form a covalent disulfide bridge.  The 
ectodomain of A56 contains three cysteines.  The first two are in an Ig-like domain and 
have been hypothesized to form an intramolecular disulfide bond (51).  Thus the 3rd 
cysteine is unpaired and we hypothesized that it was this cysteine that formed a disulfide 
bond with VCP’s free N-terminal cysteine.  We constructed expression plasmids for 
transient transfection of uninfected cells.  We made plasmids that expressed VCPwt, 
VCPmut, A56wt and a series of A56 mutants, where each mutant had one of the three 
ectodomain cysteines mutated to a serine residue.  We found that VCP can only be 
expressed on the cell surface when it was cotransfected with the A56 plasmid.  Mutating 
the first two cysteines of A56 (alone or together) did not affect surface expression of 
VCP.  However, when the third cysteine at position 162 was mutated, VCP surface 
expression was lost.  This loss of expression closely mirrors what was seen when wild-
type A56 was transfected with VCPmut.  Taken together, these mutations allowed us to 
conclude that the A56/VCP complex is formed by a disulfide bridge between the N-
terminal cysteine (C20) of VCP and third cysteine (C162) of A56.  Surface expression of 
VCP on infected cells can result in additional functions.  As a secreted protein, VCP had 
been thought to act by decreasing complement activation in the extracellular milieu 
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around an infection.  Since VCP is also expressed at high levels on the cell surface, this 
meant that the protein could be directly protecting infected cells from the host 
complement attack.  Work done in our lab has supported this hypothesis, as cells infected 
with a VCPmut virus are more susceptible to complement lysis than those infected with 
wild-type virus (36). 
 
 
Extensions of surface expression of viral complement control proteins to other 
poxviruses 
Many other poxviruses besides VACV encode complement control proteins.  Of these, 
the best characterized are SPICE from smallpox, MoPICE from monkeypox, and EMICE 
from ectromelia (mousepox) (67-69, 85, 98, 114).  They all share significant homology to 
VCP and are made up of the same SCR domain repeats.  SPICE and EMICE both contain 
four SCR domains, while MoPICE, due to a point mutation that results in an early stop 
codon, contains three SCR domains and a few residues of the 4th SCR domain.  EMICE 
and SPICE contains the same free N-terminal cysteine as VCP; while MoPICE does not 
have this cysteine, there is an unpaired C-terminal cysteine.  In chapter four, we found 
that SPICE is expressed on the surface of cells only when VACV A56 is contransfected.  
Like VCP, SPICE surface expression is lost when A56mut3 is co-transfected.  This 
finding was somewhat expected, as VCP and SPICE have identical first SCR domains 
and their A56 proteins are highly homologous.  These findings suggest that SPICE could 
also protect infected cells from complement attack during a smallpox infection.  Our data 
with EMICE was also interesting.  Both EMICE and ectromelia virus A56 are less similar 
to VACV than the smallpox homologs.  We found that there was only minimal surface 
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expression of EMICE when co-transfected with VACV A56.  However, data from 
infected cells showed a high level of EMICE surface expression.  We found that while 
surface expression of EMICE in the presence of VACV A56 was low, when EMICE was 
co-transfected with the plasmid expression ectromelia A56, high EMICE surface 
expression was seen.  Excitingly, this means that not only is the complement control 
protein/A56 interaction preserved in different poxviruses, but also that co-evolution of 
these two proteins may be occurring. 
 In contrast to the work with VCP, SPICE, and EMICE, we found that surface 
expression of MoPICE is minimal in cells co-transfected with VACV A56 or it’s own 
cognate A56 protein.  Based on work with the truncated VCP proteins, where a C-
terminal cysteine on the first SCR could result in surface expression, We took this finding 
with MoPICE, which has a free C-terminal cysteine after the 3rd SCR domain, to mean 
that the free cysteine on a complement control protein must be on the first SCR domain to 
efficiently interact with A56.  This may provide some insight into the residues needed for 
the initial interaction of an SCR with A56 to allow the disulfide bond form.  The low 
level of surface expression of MoPICE on transfected cells was also seen with 
immunofluorescence staining of monkeypox virus infected cells.  MoPICE stains faintly 
on the infected cell surface, but at much lower levels than VCP on VACV-infected cells. 
 
The importance of the A56/VCP complex to in vivo pathogenesis 
The in vitro activity of VCP in regulating complement activation has been well 
characterized (50, 57, 68, 100).  Girgis et al (36) provided the first evidence of an activity 
of surface expressed VCP in vitro by studying its role in inhibiting complement-mediated 
lysis of infected cells.  There have been fewer in vivo studies that focus on the role of 
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VCP during a VACV infection.  In addition, previous in vivo studies used gene knockout 
viruses (50).  This thesis provides the first in vivo studies that specifically study the 
contribution of cell-surface VCP to virulence.  In chapter four, we studied viruses that 
produced VCPmut in both intradermal and intranasal models of mouse infections.  We 
found that in intranasal infections, a VCPmut-producing virus was as attenuated as a 
VCPko virus.  Intradermally, vvVCPko was attenuated relative to vvVCPwt, while 
vvVCPmut had an intermediate phenotype.  This suggested that surface expression of 
VCP contributes to virulence; this is in addition to the effect of soluble VCP.  However, 
because VCPmut cannot form dimers, we could not say with 100% certainty that the 
attenuation we saw was due to the absence of the A56/VCP complex on the surface of 
infected cells. 
In chapter four we generated mutant A56 proteins and identified one that could 
not bind VCP, but was unaffected in its other function (i.e., binding K2, which results in 
a complex that can inhibit syncytia formation and superinfection).  In chapter five, we 
constructed a recombinant virus expressing this mutated A56 protein, and tested it 
alongside its parental A56 knockout virus and the A56 rescue virus.  We found that 
vvA56mut3 was attenuated in an intranasal model of infection, even though vvA56ko 
was not.  We interpreted this to mean that the A56/VCP complex contributes significantly 
to virulence in this model.  In an intradermal model of infection, vvA56ko is significantly 
attenuated compared to vvA56rescue.  We took this to mean that either the A56/VCP or 
A56/K2 complex is important for pathogenesis in this model; it is also possible that both 
complexes contribute.  Like A56ko, vvA56mut3 is also attenuated after intradermal 
infection.  We concluded that the A56/VCP complex is important for full virulence in this 
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model; the slight differences between vvA56ko and vvA56mut3 may mean that the 
A56/K2 complex also plays a role. vvA56mut3 forms the same size lesions as VCPmut; 
this supports the conclusion that the lack of the A56/VCP complex is what attenuates 
these viruses.  Importantly, no differences were seen between vvA56mut3 and 
vvA56rescue in C3-/- mice.  This means that the differences we saw in the other models 
were likely due a fully functional complement system and the absence of surface 
expressed VCP. 
 
Future directions 
There are other sets of experiments that could be done to further this work and our 
understanding of the contribution to surface expression of VCP during a viral infection.   
In chapter four, we studied SPICE, but only in a transfection system and only with 
vaccinia A56.  It may be possible to observe SPICE in the context of a variola virus 
infection at the CDC.  From a biochemical standpoint, further mutagenesis of A56 around 
the third cysteine and the first SCR domain could be performed to see what residues are 
important for the initial interaction between A56 and VCP.  Recent proteomic work 
showed that VCP is present on some EV particles, presumably bound to A56.  However, 
experiments have not yet been done to determine whether virion-bound VCP is protective 
against complement.  Our work with a panel of viruses with mutations in VCP and a 
panel of viruses with mutations in A56 makes direct comparisons between these sets of 
viruses difficult because the starting parental viruses were different.  Thus creating a 
series of virus mutants (K2ko, VCPmut and VCPko, A56ko, and A56mut3) from the 
same parental virus with rescues would allow for more direct comparisons of each 
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mutant’s contribution to virulence.  Such a panel of viruses would allow more definitive 
conclusions about the contribution of the VCP homodimer vs. VCP surface expression to 
VACV pathogenesis. 
 In conclusion, this thesis has provided evidence that VCP and A56 form a 
covalently bonded complex at the surface of infected cells, and this complex is necessary 
for full viral pathogenesis in two different models of infection. 
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